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Predictors of HPV vaccination intent for daughters were assessed among mothers 
of female survivors of childhood cancer and a community control sample of mothers. 
Mothers of female survivors of childhood cancer (N = 153) presenting at St. Jude 
Children’s Research Hospital for After Completion of Therapy Clinic and a control group 
of mothers of healthy adolescent females (N = 44) completed a questionnaire which 
included the measurement of demographic and medical information, knowledge of HPV 
and cervical cancer, self-efficacy, and health beliefs regarding HPV and cervical cancer. 
Current vaccination rates were examined and significant factors that influence mothers’ 
intent to have their daughter vaccinated against HPV were identified. Results were based 
on correlations and linear regression analyses. The constructs measured were entered as 
predictors of vaccination intent. For mothers with vaccine naïve daughters, intent to 
vaccinate in the future was negatively correlated with daughter’s age and perceived 
barriers, and positively correlated with perceived severity, perceived benefits, and self-
efficacy. Four factors and two covariates (group, daughter’s age, perceived severity, 
barriers, benefits, and self-efficacy) accounted for more than 37% of the variance in 
intent. Daughter’s age and perceived benefits demonstrated significant unique effects on 
intent to vaccinate. Findings of the current study further our understanding of familial 
decision-making about child and adolescent health through identification of factors 
influencing HPV vaccination among female survivors of childhood cancer and healthy 
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Vaccinating Daughters against HPV: Comparing Mothers of Childhood Cancer Survivors 
with Community Controls 
Genital human papillomavirus (HPV) is the most common sexually transmitted 
infection. Vaccines to prevent HPV infection have been licensed by the U.S. Food and 
Drug Administration (FDA) for use in females and males. Vaccination rates among 
females with a history of childhood cancer, a population at higher risk for HPV-related 
complications, have yet to be documented. Many survivors are at high risk for HPV 
complications because of the direct and indirect effects of cancer treatment; therefore 
HPV vaccine uptake is particularly important for females surviving cancer. The 
Children's Oncology Group's Long-Term Follow-Up Guidelines for Survivors of 
Childhood, Adolescent, and Young Adult Cancer (COG LTFU) recommends HPV 
vaccination for all eligible female childhood cancer survivors. Given that the HPV 
vaccine was approved for widespread use in females only 5 years ago, and in males only 
2 years ago, the extant literature is only beginning to document early rates of HPV 
vaccination uptake among the general population. In order to facilitate future vaccine 
uptake it is also important to identify factors that influence intentions to obtain the HPV 
vaccine. The present study is the first to investigate rates of HPV vaccination among 
adolescent female cancer survivors and to compare families of adolescents treated for 
cancer to their healthy peers on a number of HPV-related factors. The relations of HPV-
related factors, medical and demographic factors in particular, to mothers’ intent to 
vaccinate daughters against HPV were also examined.   
Genital HPV is the most common sexually transmitted infection (Sauvageau, 
Duval, Gilca, Lavoie, & Ouakki, 2007; Weinstock, Berman, & Cates, 2004). 
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Epidemiological studies indicate that approximately 50–70% of sexually active women 
contract HPV at some point during their lifetime (Mariam, 2005). More specifically, the 
prevalence of HPV has been estimated to be as high as 39.6% among 14- to 19-year-olds 
and 49.3% among 20- to 24-year-old sexually active females (Dunne et al., 2007). 
Human papillomavirus infection rates are highest in younger women and rise sharply 
soon after the mean age of first sexual activity – between 16 and 17 years for females 
(Kahn, Rosenthal, Succop, Ho, & Burk, 2002; Winer et al., 2003; Wulf, 2002). 
HPV is a double-stranded DNA virus that infects squamous epithelia, and 
infection with oncogenic HPV strains is a contributing factor to different types of 
anogenital cancer including cervical, vaginal, vulvar, penile, and anal cancers, as well as 
head and neck cancers. Of the over 100 identified types of HPV, approximately 40 strains 
affect the genital tract (Munoz et al., 2003). Screening for cervical cancer is performed by 
Papanicolaou (Pap) testing to identify abnormal cells in the cervix that may lead to 
cancer. Some HPV infections may be asymptomatic and most women with HPV 
infections have normal Pap test results, as the infection clears without causing any kind 
of abnormality (National Cancer Institute, 2007). However, all HPV strains have the 
potential to cause abnormal results, indicating development of precancerous cells in the 
cervix (American College of Obstetricians and Gynecologists, 2004). Although most 
HPV infections will resolve on their own, persistent human papillomavirus infection is a 
necessary cause of cervical cancer (Ault, 2007). Although HPV occurs most often in 
sexually active adolescents and women aged 15 to 24 years, cervical cancer diagnosis 
most often occurs in women over the age of 40, with median age at diagnosis for all 
cervical cancer patients being 47 to 48 years (Ries et al., 2006; Watson et al., 2008). 
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 Recent efforts to promote cancer prevention and control practices have led to the 
development of vaccines against HPV, which are currently available and have been 
demonstrated to be clinically effective (CDC, 2007; Harper et al., 2006; Koutsky & 
Harper, 2006). In June of 2006, the U. S. FDA  approved Gardasil, a quadrivalent vaccine 
that protects young women from the 4 types of HPV (HPV types 6, 11, 16, and 18) which 
account for 70% of cervical cancers and 90% of genital warts cases (Villa et al., 2005). In 
clinical trials, Gardasil has demonstrated nearly 100% efficacy in protecting females 
against these 4 HPV types (Villa, 2007; Villa et al., 2006). Additionally, the vaccine is 
generally well tolerated and highly immunogenic, indicating good safety and 
immunogenicity (Reisinger et al., 2007). In October of 2009, the FDA licensed Cervarix, 
a bivalent vaccination against HPV types 16 and 18, and was approved for use in females 
aged 10 through 25 years (Centers for Disease Control and Prevention, 2010a). 
The FDA approved the Gardasil vaccine for girls and women between the ages of 
9 and 26 years (FDA, 2006b). Because it is recommended that girls receive the series of 
injections prior to the onset of sexual activity, universal HPV vaccination is 
recommended by the Advisory Committee on Immunization Practices (ACIP) for 
adolescent females aged 11- and 12-years-old; the series of three injections is 
administered over six months and can be started as young as 9 years of age (CDC, 2007). 
It is also recommended that young women aged 13 to 26 years who have yet to be 
vaccinated or complete the 3-shot vaccine series still receive the HPV immunization - 
known as a catch-up vaccination (CDC, 2007). In the fall of 2009, the FDA also licensed 
the HPV vaccine for use in males between the ages of 9 and 26 years for the prevention 
of genital warts (FDA, 2010). 
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The projected benefits of mass HPV immunization are considerable. The 
American Cancer Society estimates a possible reduction of cervical cancer risk by 70% 
or more with the vaccine’s use over many decades (Saslow et al., 2007). Such a decline 
in cervical cancer rates will depend on the number of carcinogenic HPV types targeted by 
the prophylactic vaccine, durability of protection, degree of vaccination coverage of the 
at-risk population, and whether the medical community and the public continue to follow 
recommended screening guidelines (Saslow et al., 2007). Furthermore, published studies 
have estimated the HPV vaccine to demonstrate significant cost-effectiveness (Huang, 
2008; Markowitz et al., 2007; Zimet, Shew, & Kahn, 2008). Therefore, promotion of 
HPV vaccine uptake is critical.  
As the human papillomavirus vaccine has been widely available for only five 
years, sparse literature exists indicating precisely how many females have received (and 
completed) the immunization series to date. Medical audits conducted one year post FDA 
approval of the vaccine found that as of early 2008, only 10% of age eligible girls and 
young women initiated and only 2% had completed the three-dose series (Sheinfeld 
Gorin, Franco, & Westhoff, 2008). Numerous clinical trials were conducted prior to 
Gardasil’s approval by the U.S. FDA, and at least 21,000 females were vaccinated over 
four clinical trials (FDA, 2006a). In a national study conducted by the Centers for 
Disease Control and Prevention (CDC) to estimate vaccination coverage among 
adolescents, it was recently reported that 44.3% of adolescents aged 13-17 years received 
at least one dose of the HPV vaccine series and 26.7% completed the 3-dose vaccine in 
2009 (Centers for Disease Control and Prevention, 2010b). 
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Certain populations are at an increased risk for HPV infection and HPV-related 
health problems. For example, the prevalence of cervical squamous intraepithelial lesions 
and the incidence of cervical cancer caused by HPV are higher among women who are 
human immunodeficiency virus (HIV)-positive (Palefsky, 2007, 2009). Similarly, 
patients who receive immunosuppressive therapy following organ transplantation have 
shown increased anal intra-epithelial neoplsia due to HPV-infection (Roka et al., 2004). 
Due to the direct and indirect effects of cancer treatment and its suppression of immune 
functioning, female survivors of childhood cancers are also at increased risk for HPV-
related health consequences (Klosky et al., 2009). Additional research is needed to 
understand the current prevalence of HPV vaccination, particularly among populations at 
high risk for HPV infection and related complications.  
Female Survivors of Childhood Cancer 
The HPV vaccine is an important advancement for public health with specific 
benefits relating to the primary prevention of cervical and other cancers. Research must 
focus on understanding the factors which relate to HPV vaccination particularly among 
high-risk populations such as groups who are immunocompromised or are less likely to 
engage in Pap screening as recommended. Female survivors of bone marrow 
transplantation as part of cancer treatment are at significantly increased risk for abnormal 
Pap test results, precancerous markers of cervical cancer known as cervical dysplasia, and 
second cancers including cervical cancer (Klosky et al., 2009). As a result, study of HPV 
vaccination intent and completion is needed among female survivors of childhood cancer, 
who are at greater risk for HPV-related complication due to altered immunity post cancer 
treatment, particularly for those who have experienced bone marrow transplant. 
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Initiation of the immune response to HPV infection is largely orchestrated by 
epithelial cells within the lower genital tract. Via pathogen recognition, expression of 
antimicrobial mediators, and production of cytokines and chemokines that direct the 
immune response, genital tract epithelial cells play a key role in immunity to HPV 
(Quayle, 2002). Cancer patients treated with therapies toxic to mucosal surfaces, such as 
anthracyclines and radiotherapy, may be more prone to HPV infection simply on the 
basis of impaired genital tract epithelial cell function. Survivors with chronic graft-
versus-host disease that involves the genital tract mucosa may also have impaired 
epithelial cell function. When considering the potential for an underlying genetic 
predisposition to malignancy in patients already treated for cancer during childhood, one 
can argue it is essential to study factors relating to intent to receive and completion of the 
HPV vaccine in this group. 
In a study examining second malignancies among 3,182 children who underwent 
allogeneic bone marrow transplant as part of treatment for acute lymphoblastic leukemia, 
researchers reported that the estimated cumulative risk for a new solid cancer was 11% 
by 15 years after transplant, which represented a 34-fold increased risk compared with 
expected population-based rates (Socie et al., 2000). Sasadeusz and colleagues (2001) 
documented a significantly higher rate of cervical cytological abnormalities in recipients 
of both allogeneic and autologous transplants when compared to the general population. 
The proportion of abnormal Pap smears is typically 3% to 6% among healthy women; 
however, for women 3 years post bone marrow transplantation, disproportionate rates of 
abnormal Pap smears ranged from 14% to 54% and from 4% to 33% for allogeneic and 
autologous transplant recipients, respectively (Sasadeusz et al., 2001). 
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In a recent study of 38 females followed 7 years after allogeneic transplant, 43% 
had abnormal Pap cytology smear findings, with 20% experiencing HPV-related high-
grade (and 14% experiencing low-grade) squamous intraepithelial lesions (Savani et al., 
2008). Furthermore, those women experiencing chronic GVHD post-transplant that 
required prolonged systematic immunosuppressive therapy for >3 years were at the 
highest risk for dysplasia and more aggressive abnormalities of the cervix. Finally, a 
retrospective study examining the occurrence of new solid cancers among 2,129 patients 
who underwent bone marrow transplantation between 1976 and 1998 reported that the 
cumulative probability for developing a solid cancer was nearly 15% at 15 years after 
bone marrow transplant (Bhatia et al., 2001). More specifically, transplant recipients had 
a 13-fold increased risk for the development of cervical cancer compared with expected 
population-based rates. 
These findings may be explained by immunosuppression that permits persistent 
HPV replication that otherwise would not occur. Indeed, there is evidence in other 
settings such as renal transplantation that immunosuppression is associated with a greater 
incidence of HPV infection and cervical intraepithelial neoplasia than is seen in age- and 
parity-matched controls (Seshadri, George, Vasudevan, & Krishna, 2001). Women with 
Hodgkin lymphoma and those treated with pelvic irradiation are also more susceptible to 
HPV-related complications, likely due to compromised immune functioning (Klosky et 
al., 2009). In the largest study of HPV infection among women with Hodgkin lymphoma 
performed to date, a retrospective review of medical charts of 666 patients consecutively 
treated at The University of Texas M. D. Anderson Cancer Center between 1963 and 
1982 revealed that among the 85 study participants, 46% had HPV infection and related 
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neoplasia of the cervix or anogenital region (Katz, Veanattukalathil, & Weiss, 1987). 
Additionally, women treated with pelvic irradiation are significantly more likely to 
experience HPV-related cervical and vaginal dysplasia and carcinomas of the genital 
tract, which are attributed to recurrence of original malignancy, mutation of 
cervicovaginal mucosa cells due to radiation exposure, natural HPV dysplastic processes, 
or a combination of these mechanisms driven by treatment-induced immunosuppression 
(Fujimura, Ostrow, & Okagaki, 1991). 
In sum, there is mounting evidence of increased risk for HPV-related health 
consequences for females with history of Hodgkin lymphoma, those treated with pelvic 
irradiation, and those who have undergone bone marrow transplant. As of yet, it is 
unclear is this added risk will extend to all forms of childhood cancers or all methods of 
childhood cancer treatment. It is nonetheless important to address the potential protective 
health benefits HPV vaccination may offer adolescent female childhood cancer survivors 
who are at increased risk for HPV-related complications. 
In addition to treatment-related predisposition, survivors of childhood cancer also 
engage in behaviors which increase their risk for HPV infection and complications. For 
example, survivors of childhood cancer are also at increased risk for infertility, and 
female survivors who perceive themselves to be infertile may be at increased risk to 
engage in riskier sexual behaviors including lack of birth control use (Zebrack, Casillas, 
Nohr, Adams, & Zeltzer, 2004). Relatedly, health care screening utilization in 
survivorship has been an issue among female survivors of childhood cancer as they are 
less likely than their healthy siblings to have had a recent Pap smear (Hudson et al., 2003; 
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Oeffinger et al., 2004; Yeazel et al., 2004), with Hispanic survivors having been the least 
likely to have had a Pap test within the last 3 years (Castellino et al., 2005). 
Cognitively speaking, inattention and hyperactivity are commonly reported late 
effects of childhood cancer treatment. These symptoms have been associated with 
increased risky sexual behaviors, such as engagement in casual sex and infrequent 
condom use, among young adults diagnosed with Attention Deficit Hyperactivity 
Disorder (ADHD) as children (Flory, Molina, Pelham, Gnagy, & Smith, 2006). In a 
comparison of adolescents and young adults that had been diagnosed with ADHD as 
children within a community control group, a greater percentage of the hyperactive group 
had become parents at follow-up and had been treated for a sexually transmitted disease 
(Barkley, Fischer, Smallish, & Fletcher, 2006). Engagement in risky sexual behaviors 
could place survivors with problems with inattention/hyperactivity at greater risk for 
contracting sexually transmitted infections such as HPV. 
Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and 
Young Adult Cancers have been developed by the Children’s Oncology Group (2006) and 
serve as the gold standard in regard to the management of late effects that may arise due 
to treatment of pediatric cancer. The recommendations, resulting from thorough literature 
review and collective multidisciplinary clinical experience, are intended to increase 
awareness of potential late effects and to standardize as well as improve follow-up care 
for survivors of childhood cancers. In March of 2006, the second version of these 
guidelines was published based on updated research findings related to late-effects of 
pediatric cancer treatment, and a third version of these guidelines was released in October 
2008. Included in these guidelines are recommendations for health counseling regarding 
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the benefits of HPV vaccination for female patients who have survived childhood cancer. 
The endorsement of the HPV vaccine by the panel generating the COG LTFU Guidelines 
is a testament to the importance of the HPV vaccine in this relatively high-risk 
population. Indeed, medical, behavioral and cognitive late effects of cancer treatment 
place survivors of childhood cancer at increased risk for HPV-related complications, and 
identifying factors which influence familial decisions to obtain HPV vaccination is 
warranted in this population. The present study examined the predictive influence of the 
factors discussed below for intent to have daughters vaccinated among mothers of 
understudied target populations by comparing at-risk youth with healthy peers. Such 
comparisons will address differences in predicative factors for intent to vaccinate and will 
assist in tailoring future interventions to promote HPV vaccinations among high-risk 
populations. 
Influential Factors on Intent to Vaccinate Daughters for HPV 
To facilitate future vaccine uptake it is important to identify factors that influence 
intentions to obtain the HPV vaccine. Immunization against HPV is likely a familial 
decision-making process. Parents/caregivers often determine whether to vaccinate their 
daughters and therefore are salient to the vaccine’s utilization. Parents are their children’s 
and adolescents’ primary means for obtaining health care, as states conventionally 
recognize the right of caregivers to determine health care decisions on their children’s 
behalf (Boonstra & Nash, 2000). 
Because the vaccine for HPV is relatively new (approved for use among females 
by the FDA June, 2006), little is known about the complexity of familial and other factors 
which may affect decision-making regarding the HPV vaccination, particularly among 
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high risk populations which may be at relatively increased risk for HPV-related 
complication. Vaccination rates among high risk populations are unknown, and there is a 
need for greater understanding of the complicated decision-making process for families 
to vaccinate daughters against HPV, as it not only involves issues related to vaccination 
but also adolescent sexual behavior. In a recently developed conceptual model (Gamble, 
Klosky, Parra, & Randolph, 2009), guided by the Health Belief Model, Theory of 
Planned Behavior, and Social Learning Theory, it was proposed that the following 
variables may have direct predictive influence on mothers’ intent to have daughters 
vaccinated for HPV: Health Belief Factors, Cues to Action including Sexual 
Communication with Daughters, Knowledge of HPV-Related Health Risks, Socio-
Environmental Factors, Self-Efficacy, and Medical and Demographic Factors. Appendix 
A illustrates the conceptual framework for understanding familial decision-making as it 
relates to HPV vaccination. Given the large number of factors that may contribute to 
intent to vaccinate daughter’s for HPV, and the lack of research pertaining to HPV 
immunization among cancer survivors, the focus of this paper has been narrowed to 
include medical and demographic factors, health beliefs, self-efficacy, and knowledge of 
HPV and cervical cancer. Focusing on these more basic yet relevant factors is a starting 
point to identify those most influential in predicting HPV vaccination among families 
whose daughters have survived childhood cancers. Future studies will continue to further 
examine additional constructs within the conceptual model. 
Completion of HPV immunization is first influenced by intentions to receive the 
HPV vaccine. The conceptual model helps to identify significant predicting factors that 
influence mothers’ intent to have their daughters vaccinated for HPV. The Theory of 
 
12 
Planned Behavior proposes that an individual’s attitudes toward a behavior, perceptions 
of the beliefs of significant others (norms), and perceived control over the behavior 
influences his or her behavioral intent, which in turn drives engagement in the actual 
behavior (Ajzen, 1991). Such a theory assumes behavioral intention is the most 
significant determinant of engaging in a behavior, with intent initially influenced by 
personal evaluation of a behavior and beliefs about whether important people would 
approve or disapprove of the behavior (Rimer & Glanz, 2005). In other words, multiple 
factors influence HPV vaccine intent, which subsequently predicts HPV vaccine 
completion. Numerous factors likely fall between HPV vaccine intent and subsequent 
completion of vaccination. However, this exploratory study will focus exclusively on 
factors predictive of mothers’ intent to have daughters vaccinated for HPV, rather than 
those which influence actual immunization implementation. In order to promote the 
vaccine among those who have yet to initiate HPV immunization, it is important to assess 
future intent to vaccinate and identify factors that predict intentions of getting the 
vaccine. 
Health Beliefs Factors 
The Health Belief Model, previously applied to a number of health behaviors 
including vaccination and contraceptive practices, proposes four primary constructs that 
aid in accounting for people’s readiness to act (Rimer & Glanz, 2005). They are 
perceived susceptibility, perceived severity, perceived barriers, and perceived benefits 
(Glanz, Rimer, & Lewis, 2002). Two additional constructs, cues to action and self-
efficacy, have been added in recent years; however, there has been less empirical support 
in studying these last two factors as part of the Health Belief Model. Within the 
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conceptual model, the health belief factors are largely made up of components from the 
Health Belief Model, as these constructs have previously been demonstrated to influence 
HPV vaccine acceptance (Brabin, Roberts, Farzaneh, & Kitchener, 2006; Gerend, Lee, & 
Shepherd, 2007), but may also include may include attitudes and beliefs held by mothers 
regarding immunization. Perceived susceptibility is one’s subjective perception of the 
risk of contracting a health condition, such as HPV or cervical cancer. For example, how 
likely is my daughter to become infected with HPV? Denial of any need to vaccinate 
daughters has characterized parental resistance to vaccinating daughters (Constantine & 
Jerman, 2007). Perceived severity is one’s opinion of how serious a condition and its 
consequences are. For example, parents may question the severity of treatment for their 
daughters’ HPV-related conditions, or social consequences such as disclosure of HPV 
infection to sexual partners, health care professionals, and insurance companies. Applied 
to the HPV vaccine, perceived benefits would include reducing a daughter’s risks of 
contracting HPV thus reducing her chance of developing cervical cancer. Perceived 
barriers are opinions on the tangible, as well as psychological, costs of obtaining HPV 
vaccination for one’s daughter including pain associated with HPV injections, financial 
costs, perceptions of side-effects and unknown risks. Belief that HPV immunization 
would promote earlier initiation of coitus and encourage sexual activity has characterized 
the opposition that some parents have to the vaccination (Brabin et al., 2006). 
Knowledge of HPV-Related Health Risks 
Knowledge of HPV and its link to cervical cancer likely affects intention to 
vaccinate. Mothers are more knowledgeable of HPV health risks when they understand 
HPV transmission, are educated on the link between HPV and cervical cancer, and are 
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familiar with HPV treatment and vaccination safety and efficacy. Low levels of HPV 
knowledge have been observed among parents and adolescents, as few have heard of 
HPV or a vaccine. Prior to HPV vaccination approval, Brabin et al. (2006) surveyed 
parents regarding potential acceptance of such a vaccination. Findings indicate that few 
parents knew of HPV or a vaccine for HPV, however 81% reported they would agree to 
have their child vaccinated. Parents with higher knowledge levels report greater 
acceptance of the vaccine, whereas lack of disease-specific knowledge and questions 
about vaccine safety have been linked to rejection of vaccination against STIs. 
Self-Efficacy  
Another proposed influence on HPV vaccine intentions occurs by means of self-
efficacy. As it relates to the Health Belief Model, self-efficacy is one’s confidence in her 
ability to successfully take action. Self-efficacy is not only a component of the Health 
Belief Model but also a construct of Bandura’s Social Cognitive Theory, a theory which 
may be relevant in health behavior (as cited in Glanz et al., 2002). Self-efficacy in Social 
Cognitive Theory is “the person’s confidence in performing a particular behavior and in 
overcoming barriers to that behavior” (Glanz et al., 2002, p. 169). Little empirical 
research has been conducted to examine self-efficacy factors linked to HPV vaccination. 
Proposed examples of mothers’ self-efficacy are perceived ability to get daughter to 
physician clinic, perceived ability to effectively communicate with daughters about 
sexual topics and successfully negotiate with teens regarding completion of the 3-shot 
vaccination series. An individual can engage in behavioral changes, even in the face of 




Medical and Demographic Factors  
Parent and adolescent medical and demographic factors are directly related to 
intention to seek HPV vaccination. Medical factors represent parent and adolescent health 
histories. Demographic factors are population characteristics. Prior research has 
examined the association of age, gender, ethnicity, parent education, marital status, and 
income with acceptance of HPV vaccination. Previous studies have found no association 
between vaccine acceptance and parent socio-demographic factors including ethnicity, 
age, and religion (Brabin et al., 2006). Also, while no significant effects for parent age or 
gender emerge, Hispanic parents were more likely to endorse vaccination whereas Asian-
American and African-American parents were less likely to do so (Constantine & 
Jerman, 2007). Proposed medical influences on acceptance of HPV vaccination may 
include history of cancer, abnormal Pap test results and history of Pap screening, history 
of STI testing, and childhood immunization records. Among mothers from a community 
health clinic, correlates of HPV immunization acceptability included history of HIV 
testing (Gerend et al., 2007). Slomovitz et al. (2006) report that a history of abnormal Pap 
tests has not been shown to be associated with women’s acceptance of the HPV vaccine 
for either themselves or their children. However, mother’s willingness to vaccinate 
offspring against HPV was associated with whether her child had received all previously 
recommended immunizations. Evaluating the predictive influence of such demographic 
and medical characteristics on vaccination intent was important for the current study, as 




 Limitations exist within the literature at this time. Most studies have surveyed 
parents, adolescents, and physicians regarding attitudes about HPV vaccine acceptance, 
yet little is known about intent for getting the vaccine and actual vaccination rates. There 
is a lack of application of theory to determine health factors from a range of domains 
simultaneously influencing familial decision-making regarding HPV immunization. 
Finally, research has yet to examine HPV vaccination issues among those at high risk for 
HPV-related complication, such as immunocompromised persons and female survivors of 
childhood cancer, in particular. 
Present Study 
Study Aims 
The purpose of the present study was to examine the influence of HPV-related 
factors on mothers’ intent to vaccinate daughters against HPV. This study is unique in 
that it targeted a population at higher risk for HPV-related complications (i.e., daughters 
with a history of childhood cancer) as well as a control group (i.e., healthy daughters). 
The present study furthers current understanding of familial decision-making about child 
and adolescent health through identification of factors influencing HPV vaccination 
among families. This is the first study to compare families of adolescents treated for 
cancer to their healthy peers on a number of HPV-related factors, which has implications 
for tailoring interventions based on medical risk factors. 
Aim 1 of the present study was to examine current HPV vaccination rates among 
families with preadolescent/adolescent females. Because little is known about HPV 
vaccination rates among female survivors of childhood cancer, comparisons were made 
between cancer and controls groups with regard to current vaccination rates as well as 
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intent to vaccinate. Aim 2 was to compare hypothesized influences on intentions to obtain 
the HPV vaccine (i.e., medical and demographic factors, cervical cancer/HPV 
knowledge, health beliefs, and self-efficacy) between cancer and control groups.  
Aim 3 was to assess the relations of medical and demographic factors (i.e., 
maternal age, ethnicity, marital status, education, income, Pap history, STI history, 
daughter’s age, daughter’s immunization history, and physician recommendation for 
HPV vaccination), cervical cancer/HPV knowledge (i.e., how HPV is transmitted and 
risk factors for infection), health beliefs (i.e., perceived susceptibility, severity, barriers, 
benefits, and beliefs about decisions), and self-efficacy (i.e., mothers’ ability to talk with 
physician, get daughter to medical clinic, complete the 3-shot series) to HPV vaccination 
intent among mothers with preadolescent/adolescent daughters. As this study is 
exploratory in nature and this area has yet to be studied in this high risk population, no 
clear expectations are made with regard to whether mothers of cancer survivors will 
vaccinate daughters at higher or lower rates than the healthy population, whether groups 
will differ on hypothesized predictors of intent, or which factors will predict intent to 
vaccinate daughters against HPV in the future. 
Method 
Participants 
The sample for the present study was comprised of mothers/female caregivers 
whose daughters are active patients in the After Completion of Therapy Clinic (i.e., ACT 
survivorship clinic) at St. Jude Children’s Research Hospital (SJCRH). The study sample 
was also comprised of mothers/female caregivers of daughters without a history of 
childhood cancer (i.e., community controls). To be accepted into the ACT clinic, patients 
 
18 
must have had a previous diagnosis of malignancy, be 5 years post diagnosis, and 
completed cancer therapy at least 2 years previously. Participants for the present study (a) 
were mothers/female primary caregivers of active patients who participate in the After 
Completion of Therapy (ACT) clinic at SJCRH, (b) had daughters aged 9 to 17 years of 
age at time of study enrollment, (c) were proficient in reading and writing English, (d) 
were cognitively intact such that the study questionnaire could be understood and 
completed, and (e) completed signed informed consent consistent with institutional 
guidelines. 
In order to obtain a control sample demographically most like the cancer group 
based on daughter’s age and mother’s SES and race, each mother recruited for 
participation at SJCRH was asked to provide contact information for up to 5 
acquaintances, following completion of the study questionnaire. The acquaintances were 
also mothers with daughters between the ages of 9 and 17 years-of-age, so that the 
primary distinguishing feature of mothers in the community control group and mothers in 
the cancer group was presence/nonpresence of daughter’s cancer history. Obtaining a 
control group using acquaintance methodology is likely to provide a control sample 
demographically most like the cancer group, matched on daughter’s age and mother’s 
SES and ethnicity. 
Participants in the community control sample (a) were mothers/female primary 
caregivers acquainted with participating mothers from SJCRH, (b) had daughters aged 9 
to 17 years of age at time of study enrollment, (c) were proficient in reading and writing 
English, (d) were cognitively intact such that the study questionnaire could be understood 
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and completed, and (e) completed informed consent consistent with institutional review 
board guidelines. 
Participants included 197 female primary caregivers of daughters, and the 
majority (78.7%) of the sample mothers were Caucasian. As most female primary 
caregivers (93.4%) reported being the biological mother of the index daughter, for 
simplicity’s sake, female primary caregivers are referred to as parents or mothers 
hereafter. Mothers’ mean age was 41.75 years (SD = 6.96). Daughters’ mean age was 
13.34 years (SD = 2.68). The sample was composed of 153 mothers of childhood cancer 
survivors and 44 control mothers of healthy daughters. Mothers of survivors of childhood 
cancer ranged in age from 27 to 62 years (M = 41.65, SD = 7.04), and is considered 
generally representative of the pediatric cancer population in the US. Daughters with a 
history of childhood cancer ranged in age from 9 to 17 years (M = 13.33, SD = 2.71). The 
survivor sample consisted of 75.8% whites and 18.3% African Americans. Mothers of 
healthy control daughters ranged in age from 29 to 56 (M = 42.09, SD = 6.71). Daughters 
without a history of childhood cancer ranged in age from 9 to 17 years (M = 13.36, SD = 
2.62). The control sample consisted of 88.6% whites and 2.3% African Americans. 
Procedures 
St. Jude cancer group study procedures. The present study did not involve any 
therapeutic or intervention component, but relied solely on the use of the self-report 
questionnaires. Mothers of patients from SJCRH were recruited from the ACT clinic. 
Mothers meeting study criteria were recruited consecutively within the time constraints 
of the availability of staff. That is, for every opportunity where there was staff available 
for recruitment, the researchers attempted to enroll the first available mother meeting 
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eligibility criteria, in an effort to reduce selection bias that would favor enrollment of 
patients’ mothers known to study staff or recommended by other staff. Eligible SJCRH 
mothers who agreed to participate were asked to sign a consent form following an 
explanation of the institutional review board-approved study. All participants were 
informed that their responses will remain confidential. Mothers who agreed to participate 
were asked to complete a battery of paper and pencil questionnaires that assessed factors 
predictive of HPV vaccination intent for their daughter as described below. The research 
instrument consisted of a self-administered questionnaire inquiring on demographic and 
medical information, knowledge of HPV and related health risks, health beliefs about 
HPV and vaccination, cues to action, socio-environmental influences, self-efficacy, 
sexual communication with their daughter, and vaccination intent for their daughter. The 
self-administered questionnaire (see Appendix H) was developed based on a review of 
the literature and previous research experience (Brabin et al., 2006; CDC, 2007; 
Constantine & Jerman, 2007; Davis, Dickman, Ferris, & Dias, 2004; Dempsey, Zimet, 
Davis, & Koutsky, 2006; Gerend et al., 2007; Kahn et al., 2008; Lazcano-Ponce et al., 
2001; Rosenthal et al., 2008). These measures required approximately 30 minutes to 
complete. One-hundred eighty-five eligible ACT mothers were invited to participate. Of 
those 185, 178 (96%) consented to participate in the study and 153 (86%) completed 
study questionnaires were returned. Seven eligible mothers declined to participate, stating 
that they were not interested in the study. Please see Appendix B. 
Community control group study procedures. Efforts were made to collect a 
control sample of mothers of healthy preadolescent/adolescent females demographically 
most like that of the families of patients in the ACT clinic. Mothers in the acquaintance 
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sample meeting eligibility criteria were invited to participate in the study. Acquaintances 
were contacted regarding participation in the study and the study was presented to the 
acquaintance control mother. Once the participant provided verbal informed consent for 
study participation, the same paper and pencil questionnaires that assess factors 
predictive of HPV vaccination intent for their daughter as mentioned above for the 
SJCRH parent group (see Appendix H), were sent via postal mail or via a link in a 
secured email, which ever was preferred. All participants were informed that their 
responses will remain confidential. One-hundred twenty-eight eligible control mothers 
were invited to participate. Of those 128, 72 (56%) consented to participate in the study 
and 44 (61%) completed study questionnaires. Two eligible mothers declined to 
participate, stating that they either did not have time to complete the study measure or 
were not interested in participating. Please see Appendix C. 
Both SJCRH and control participants were told that they would complete a survey 
about cervical cancer vaccination and their daughter’s health and that participation was 
voluntary. Mothers were asked to answer all questions about their daughter with a history 
of childhood cancer, or for the control group mothers, their daughter closest in age to the 
daughter from the referring St. Jude family. A number of procedures were employed to 
assure participants that their responses will remain confidential. Identification numbers 
rather than participant or patient names were used. After completing the survey, 
participants were instructed to seal it in an unmarked envelope. For SJCRH patient 
mothers, efforts to ensure confidentiality were made including the use of study code 
numbers rather than names, and the provision that information disclosed by mothers 
about sexual behavior would not be shared with medical staff or included in the 
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daughter’s medical chart. All data was stored on a password protected computer and data 
forms were kept in a locked file cabinet. Access to the data was limited to study staff. 
Following the completion of the study questionnaire, all mothers received a brief 
information sheet outlining the health risks of HPV infection and utility of HPV 
vaccination (see Appendix J). The study was approved by both The University of 
Memphis and St. Jude Children’s Research Hospital Institutional Review Boards (see 
Appendix K). 
Measures 
Appendix D summarizes the variables studied, where the items are located in the 
questionnaire, and the source which guided development of the questionnaire items. 
 Current Vaccination Status. Daughters’ HPV vaccination status was determined 
by one 4-point item. The item read “Has your daughter received the HPV vaccine 
(Gardasil or Cervarix)? Mark only one answer.” In terms of responses, the maternal 
participant marked 1 of 4 options with the stem, “My daughter has received…” (a) 0 of 
the three shot series (has NOT received any of the HPV vaccine), (b) 1 of the three shot 
series, (c) 2 of the three shot series, and (d) 3 of the three shot series (has completed the 
HPV vaccine). Responses were dichotomized to reflect those who have and have not 
initiated HPV vaccination. HPV vaccination status for mothers was also determined by 
one 3-point item. Responses were 1 (yes), 2 (no), and 3 (not sure). 
 Vaccination Intent (Primary Dependent Variable). For those mothers who marked 
the letter “A” on the above item indicating that their daughter has received 0 of the 3 shot 
series (i.e., has NOT received any of the HPV vaccine), they were asked to complete 4 
items assessing intent to vaccinate daughter for HPV. The maternal participant was asked 
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to answer 4 items with the stem, “How likely is it that you will have your daughter…” (a) 
start the HPV vaccine within the next month, (b) start the HPV vaccine within the next 6 
months, (c) start the HPV vaccine within the next 12 months, and (d) vaccinated for HPV 
in the future? Each item allowed for responses which ranged from Definitely Will Not (0) 
to Definitely Will (6). Items regarding vaccination intent were adapted from questions 
used in previous research (Constantine & Jerman, 2007). Due to missing data on some or 
all of the 4 intent items, only the final intent item (item “D” above) was used to assess for 
any future intent to vaccinate daughters, generating scores which ranged from 0 – 6, with 
higher scores indicating greater likelihood to vaccinate their daughter in the future. This 
continuous variable of HPV vaccination intent was used as the primary dependent 
variable for this study, and was only considered for those who indicated that their 
daughters are naive to HPV vaccination. 
Medical Care and Demographic Factors. All mothers/female primary caregivers 
were asked to provide information on their age, race/ethnicity, marital status, education 
level, and annual household income. Maternal marital status was categorized as 
“married,” “widowed/divorced/separated,” or “other.”  Maternal education level was 
measured as a continuous variable by seven items ranging from grade school to graduate 
degree. Additionally, annual household income for each participant was assessed using 
sixteen items ranging from $0-$9,999 to more than $150,000. Items requesting 
demographic background were adapted from previous research instruments (Brabin et al., 
2006; Constantine & Jerman, 2007; Dempsey et al., 2006). 
Maternal medical background included mothers’ history of Pap testing and STI, 
including HPV infection and cervical cancer. One item assessed whether daughters have 
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received all recommended childhood vaccinations. A final item assessed whether or not 
daughter’s doctor has recommended that she receive the HPV vaccine. Responses for all 
medical background items were 0 (no) and1 (yes). Items regarding mothers’ history of 
STI, and abnormal Pap test were adapted from previous self-report questionnaires 
(Rosenthal et al., 2008). 
General Knowledge of HPV and Related Risk Factors. Knowledge of HPV, 
cervical cancer, and HPV vaccination was measured using items adapted from previous 
work by Brabin and colleagues (2006) and from the CDC’s website for HPV vaccination 
information (CDC, 2007). Ten multiple choice items were used to assess mothers’ 
knowledge of HPV-related health risks. Participants were provided with questions and 
asked to select the correct answer from four possible answer choices. Participants scored 
1 or 0 for each response and the number of correct answers was summed to create a 
knowledge score for each participant. Scores ranged from 0-10 with higher scores 
representing more accurate responses and greater levels of HPV-related knowledge. 
Health Beliefs. The four constructs within the Health Belief Model that were 
examined included perceived susceptibility to HPV infection, severity of HPV infection, 
barriers to HPV vaccination, and benefits to vaccination. Mothers’ perception of their 
daughter’s susceptibility to HPV-related health risks compared to other girls her age was 
measured by summing five 5-point items, scored 1 (much less likely) – 5 (much more 
likely), (e.g., “Compared to other girls her age, how likely is your daughter to have an 
abnormal Pap test?”). Scores may range from 5-25 with higher scores indicating greater 
perceived susceptibility (α = .94). Mothers’ perception of the severity of HPV and related 
health risks for their daughters was measured by summing eight 5-point items, scored 1 
 
25 
(strongly disagree) – 5 (strongly agree), (e.g., “Infection with HPV can lead to a serious 
illness.”). Scores may range from 8-40 with higher scores indicating greater perceived 
severity (α = .86). Perceived barriers to vaccination was measured by summing twelve 5-
point items, scored 1 (strongly disagree) – 5 (strongly agree), with one item reverse 
scored. An example item stated, “It would be hard for me to find the time to get my 
daughter vaccinated for HPV.” Scores may range from 12-60 with higher scores 
indicating greater perceived barriers (α = .78). Perceived benefits of vaccination was 
measured by summing seven 5-point items, scored 1 (strongly disagree) – 5 (strongly 
agree), with one item reverse scored. An example item stated, “The HPV vaccine would 
greatly reduce the chance of getting cervical cancer.” Scores may range from 7-35 with 
higher scores indicating greater perceived benefits (α = .82). Items assessing health belief 
factors were adapted from the HPV Vaccine Health Beliefs Questionnaire (Cox, Cox, 
Sturm, & Zimet, 2010), a validated instrument designed to measure the maternal health 
belief constructs of perceived severity, perceived vulnerability, perceived barriers, and 
perceived benefits/efficacy as it relates to the HPV vaccine. The questionnaire’s 
instructions direct participants to respond to items on a Likert-type rating scale which 
ranges from “Strongly Disagree” to “Strongly Agree.” The predictive validity of these 
health belief factors has been established in their relationships with HPV vaccination 
acceptability among mothers of girls aged 11-16 (Cox et al., 2010). 
 Self-Efficacy. Mothers’ perceived self-efficacy to have daughters vaccinated for 
HPV was measured by six 5-point items, scored 1 (strongly disagree) – 5 (strongly 
agree). Scores may range from 6-30 with higher scores reflecting greater self-efficacy (α 
= .89). An example of an item on this scale asked mothers to respond to the following, “I 
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believe that I could get my daughter to the medical clinic.” Items regarding mother’s self-
efficacy for vaccinating daughter were adapted from a previous research questionnaire 
(Kahn et al., 2008). 
Statistical Analysis 
Differences between group means of continuous variables were examined using t 
tests, and distributions of categorical variables were compared using χ2 analyses. 
Specifically, separate tests were conducted to compare the cancer group and control 
group on each proposed influence (i.e., medical and demographic factors, cervical 
cancer/HPV knowledge, health beliefs, and self-efficacy). Of note, levels of predictor 
influences are reported for all participants, not just mothers of vaccine naïve daughters. 
Please refer to Appendix E for an overview of these findings. 
To examine the third study aim (i.e., to assess the general predictive influence of 
medical and demographic factors on HPV vaccination intent), a linear regression analysis 
was conducted. The dependant variable in the regression was mothers’ future intent to 
have their daughters vaccinated, thus utilizing only data from mothers of vaccine naïve 
daughters. Of note, only mothers with vaccine naïve daughters and complete data for all 
predictor variables were included for this analysis (n = 84). Zero-order correlations were 
first used to examine relations between all predictor variables and the outcome (intent to 
vaccinate daughter for HPV), and only predictor variables that had a significant 
association with intent (p ≤ .05) were considered in the regression model. Please refer to 
Appendix F for an overview of these correlational findings. Each variable that was 
associated with intent was included in a linear regression analysis to determine 
independent predictors of HPV vaccination intent. In order to control for developmental 
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differences as well as group status (i.e., mother of childhood cancer survivor or healthy 
control), age of daughter and daughters’ history of cancer status were entered as 
covariates. Please refer to Appendix G for an overview of the regression results. 
Statistical analyses were performed using SPSS version 19.0. 
Results 
Differences between Cancer and Control Groups 
 The first set of analyses will address Aim 2, which was to compare differences in 
hypothesized influences on intentions between cancer and control groups. 
Demographic & Medical Factors. Findings indicated that there were differences 
between cancer and control groups with regard to racial/ethnic background. Specifically, 
the mothers of cancer survivors group included significantly more minorities than the 
mothers of healthy controls group, as 9.3% of the control sample and 23.7% of the 
survivorship sample were comprised of participants of minority ethnic backgrounds. 
Groups did not differ based on maternal age nor on daughters’ age. Groups did not differ 
significantly based on mothers’ marital status. No differences in educational background 
were found between mothers in the control sample and mothers of cancer survivors.  
No differences in annual household income were reported between the control 
mothers and mothers of cancer survivors. Of note, differences in annual income were 
found between white and minority mothers, with white mothers reporting higher annual 
income, t(181) = -3.62, p < .01. 
With regard to maternal medical care, 71.1% (n = 140) of mothers reported 
receiving annual Pap tests (68.6% of survivorship mothers and 79.5% of control 
mothers), and 41.6% reported having ever had an abnormal Pap smear result (39.2% of 
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mothers of survivors and 50% of mothers of healthy controls). There was no significant 
difference in receipt of annual Pap test or abnormal Pap test results between groups. 
Further, 15.2% of mothers reported ever having a STI, 6.6% endorsed ever having an 
HPV infection, and 9 mothers (4.6%) reported a personal history of cervical cancer. 
There was no significant difference in history of STI or HPV infection between groups. 
No difference was found in maternal history of cervical cancer between groups. 
An overwhelming majority of mothers (93.9%) reported that their daughter had 
received all recommended childhood vaccinations, and only 44.7% of mothers endorsed 
that their daughter’s doctor recommended vaccinating for HPV. There was no significant 
difference between groups in receipt of childhood vaccinations or physician 
recommendation of HPV vaccination.  
Knowledge of HPV & Health Belief Factors.  The sample as a whole was 
relatively unknowledgeable regarding HPV and HPV-related health risks (N = 197, M = 
6.13, SD = 1.64). No significant difference was found between groups on HPV-related 
knowledge scores. Mothers of cancer survivors reported significantly greater perceived 
susceptibility to HPV and significantly less perceived severity for HPV and related health 
risks for their daughters than mothers of healthy control daughters. Mothers of childhood 
cancer survivors did not endorse greater perceived barriers or benefits to HPV 
vaccination for their daughters than mothers of healthy daughters. With regard to 
mothers’ self-efficacy to vaccinate daughters, mothers of cancer survivors reported no 
significant differences in perceived self-efficacy to vaccinate than mother’s of healthy 




HPV Vaccination Rates and Intent 
The next set of analyses will address Aim 1 of the present study, which was to 
compare cancer and control groups with regard to current HPV vaccination rates as well 
as intent to vaccinate in the future. 
Vaccination Status. Daughter’s vaccination status will be described first for the 
entire sample of participating mothers, followed by the sample of mothers of childhood 
cancer survivors, and control mothers. Of all mothers participating in the present study (N 
= 197), 65.99% (n = 130) reported that their daughter has not received the HPV vaccine 
series, 32% (n = 63) reported that their daughter had either initiated or completed the 
HPV vaccine series, and 2.0% (n = 4) of mothers did not answer this item. Of those 
daughters who initiated vaccination, 27% (n = 17) had received 1 of 3 shots, 14.3% (n = 
9) had received 2 of 3 shots, and 58.7% (n = 37) of daughters had received all 3 HPV 
vaccine shots and completed the vaccine series. 
Of all mothers participating in the present study (N = 197), 95.9% (n = 189) 
reported that they had not received the HPV vaccine personally, 2.0% (n = 4) reported 
having personally received the HPV vaccine series for themselves, 1.5% (n = 3) reported 
they were not sure whether or not they have received the vaccine, and 0.5% (n = 1) of 
mothers did not answer this item.  
Of the mothers of daughters with a history of childhood cancer (N = 153), 64.7% 
(n = 99) reported that their daughter had not received the HPV vaccine series, 32.7% (n = 
50) reported that their daughter had either initiated or completed the HPV vaccine series, 
and 2.6% (n = 4) did not answer this item. Of the survivorship daughters who initiated 
vaccination, 30% (n = 15) had received 1 of 3 shots, 10% (n = 5) had received 2 of 3 
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shots, and 60% (n = 30) of survivors have received all 3 HPV vaccine shots and had 
completed the vaccine series. 
Of mothers in the survivor sample (N = 153), 94.8% (n = 145) of mothers 
reported that they had not received the HPV vaccine personally, 2.6% (n = 4) reported 
having personally received the HPV vaccine series for themselves, 2.0% (n = 3) reported 
they were not sure whether or not they had received the vaccine, and 0.7% (n = 1) of 
mothers did not answer this item. 
Additionally, 70.5% (n = 31) of control mothers reported that their daughter had 
not received the HPV vaccine series, whereas 29.5% (n = 13) reported that their daughter 
had either initiated or completed the HPV vaccine series. Of the control daughters who 
initiated vaccination, 15.4% (n = 2) had received 1 of 3 shots, 30.8% (n = 4) had received 
2 of 3 shots, and 53.9% (n = 7) of daughters had received all 3 HPV vaccine shots and 
completed the vaccine series. 
Of mothers in the control sample (N = 44), 100% (n = 44) of mothers reported 
that they have not received the HPV vaccine personally. A chi-square test was conducted 
to evaluate the difference in daughters’ vaccination rate between groups (cancer and 
control; Aim 1). There was no significant difference in vaccination rate between cancer 
(33% vaccinated) and control (30% vaccinated) groups. Furthermore, no difference was 
found in vaccination rates between daughters of Caucasian mothers (29% vaccinated) and 
daughters of minority mothers (42.5% vaccinated), χ2(1) = 3.26, p > .05. 
Intent to Vaccinate. Recall that of the total sample, 65.99% (N = 130) of 
daughters were not vaccinated for HPV. Future intent to vaccinate daughters for HPV 
was measured by one item ranging from ‘Definitely Will Not’ to ‘Definitely Will,’ with 
 
31 
data collected for 120 of the 130 vaccine naïve daughters. No significant difference was 
found in future intent to vaccinate for HPV between groups. Appendix E provides an 
overview of these findings. 
Influences on HPV Vaccination Intent 
The final set of analyses address Aim 3, which was to assess the relations of 
medical and demographic factors to future HPV vaccination intent. Paring down the 
sample to include only mothers with vaccine naïve daughters and complete data for all 
predictor variables (n = 84), zero-order correlations examined relations between all 
predictor variables and the outcome (intent to vaccinate daughter for HPV). Appendix F 
provides an overview of these correlational findings. 
Future intent to vaccinate was negatively correlated with daughter’s age and 
perceived barriers. Intent to vaccinate was also positively correlated with perceived 
severity, perceived benefits, and self-efficacy. Linear regression analysis was used to 
determine significant independent predictors of vaccination intent. Each of the five 
variables associated with intent (i.e., daughter’s age, perceived severity, perceived 
benefits, perceived barriers, and self-efficacy) was included in the regression analysis, 
with group status (i.e., mother of childhood cancer survivor or healthy control) and age of 
daughter entered as covariates, and future intent to vaccinate for HPV as the dependent 
variable. Analyses revealed that the two covariates and four additional variables 
accounted for more than 37% of the variance in intent to vaccinate (R2 = .374). 
Daughter’s age (β = -0.18, p ≤ .05) and perceived benefits (β = 0.41, p ≤ .01) 
demonstrated significant unique effects on intent to vaccinate (see Appendix G). 
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The author was also interested in examining whether the relations between 
influences and intent were different for mothers in the cancer and control groups. To 
investigate this possibility, correlations were examined separately for the cancer and 
control groups. For mothers of childhood cancer survivors, future intent to vaccinate was 
negatively correlated with daughter’s age (r = -0.33, p ≤ .01) and barriers (r = -0.33, p ≤ 
.01), and positively correlated with perceived susceptibility (r = 0.28, p ≤ .05) and 
benefits (r = 0.48, p ≤ .01). For mothers of healthy control daughters, future intent to 
vaccinate was positively correlated with perceived benefits to immunization (r = 0.65, p 
≤ .01). In other words, belief that there are advantages to the immunization was related to 
intent to vaccinate for both groups of mothers. For mothers of cancer survivors, 
specifically, having a younger daughter, perceiving fewer barriers to vaccination, and 
belief that their daughter was at increased risk for HPV infection and related 
consequences were also related to future intent to vaccinate. 
To further determine whether group status moderated these relations, additional 
regression analyses were conducted. Using procedures outlined by Aiken and West 
(1991) continuous variables correlated with intent were centered, interactions terms were 
computed, and separate regressions were run for each interaction and relevant main 
effects. The interactions between group status and daughter’s age, perceived 
susceptibility, perceived barriers, and perceived benefits were not significant. 
Discussion 
The present study was conducted to address 3 primary aims: (a) to examine 
current HPV vaccination rates as well as intent to vaccinate among families with 
preadolescent/adolescent females with and without a history of cancer, (b) to compare 
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hypothesized influences on vaccination intentions to obtain the HPV vaccine (i.e., 
medical and demographic factors, cervical cancer/HPV knowledge, health beliefs, and 
self-efficacy) between cancer and control groups, and (c) to investigate the relations of 
these factors to HPV vaccination intent among mothers with preadolescent/adolescent 
daughters. 
This study is the first to investigate HPV immunization rates and intentions 
among families of childhood cancer survivors, a population at high risk for HPV 
infection and complication, and a control group of healthy peers. It also is one of only a 
few that tests components of a conceptual model designed to explain HPV vaccine intent. 
As no prior studies have examined HPV immunization rates among or intent to vaccinate 
childhood cancer survivors, it is important to note that both the survivor and healthy 
groups endorsed vaccination completion rates lower than the national average, therefore 
raising concern that  survivors of childhood cancer, and their acquaintances, are not being 
vaccinated as recommended. Results revealed that daughter’s age as well as perceived 
severity, benefits, barriers, and self-efficacy correlated with vaccine intent. Younger age 
and perceptions of vaccine benefit were also uniquely associated with future intent to 
vaccinate. Furthermore, factors which predicted HPV vaccination did not differ for 
mothers of childhood cancer survivors and mothers of healthy daughters. Each of the 
primary findings is further discussed below. 
Examination of HPV vaccination rates among mothers with and without a child 
surviving childhood cancer found that only 32% of daughters had either initiated or 
completed the HPV vaccine series. Nearly 66% of participating mothers had not 
vaccinated their daughter against HPV. Previous reports by the CDC (2010b) indicated 
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that 44.3% of adolescents in the U.S. had initiated the 3-dose vaccination series and 
26.7% had completed the vaccine in 2009. The present study’s finding of only 18.8% of 
daughters completing the vaccine series is therefore lower than the national average. 
Results also indicated no difference in vaccination rate between cancer and 
control groups, indicating that mothers of childhood cancer survivors and healthy 
controls vaccinate daughters at similar rates. This finding indicates that immunization 
recommendations are not being met for the general population, and that Long-Term 
Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers 
are not being followed for female adolescent cancer survivors. Many childhood cancer 
survivors, particularly those treated with hematopoietic stem cell transplantation or pelvic 
irradiation and those diagnosed with Hodgkin lymphoma, experience persistent immune 
compromise, and impaired immune function appears to be responsible for increased rates 
of cervical and oral dysplasia (Klosky et al., 2009). As survivors are at increased risk for 
HPV infection and related adverse health effects, efforts to improve HPV vaccination  in 
this population is warranted. 
One possible explanation for the relatively low vaccination rate in this study is 
that a majority of the study sample was comprised of mothers of adolescent cancer 
survivors whose daughters receive a sizable portion of their medical care from the study’s 
recruitment facility. As of yet, this medical setting does not offer HPV vaccination; 
therefore, mothers would have had to have independently pursued vaccination for their 
daughters in medical settings other than the recruitment facility – a potential barrier to 
vaccination. Furthermore, if childhood cancer survivors receive additional medical care 
from  community providers who are aware of the COG LTFU immunization 
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recommendations but assume that the patient’s oncologist is administering the vaccine 
series, the community clinicians may be less likely to address the HPV vaccination issue 
with the patient and her family. The question then arises, if adolescent cancer survivors 
were offered the HPV vaccination by their oncologist or other medical providers at 
annual ACT visits, would the vaccination rate for survivors then increase or exceed that 
of the general population? 
Additionally concerning was the finding that the community control sample of 
mothers also endorsed vaccination rates lower than the national average. Although it is 
unclear why this finding emerged, one possible explanation is the present study’s small 
sample size of control mothers (n = 44) is unlikely to be as accurate of a representation of 
the general population of adolescent females as the CDC’s sample of over 9,600 females 
with vaccination records. 
Intent is an indication of a person’s readiness to engage in a particular behavior 
(Ajzen, 1991), and a recent study demonstrated high parental intentions to vaccinate 
daughters against HPV (Gerend, Weibley, & Bland, 2009). In a sample of first-year 
college females, Juraskova and colleagues (2011) reported that when asked whether they 
intended to receive the HPV vaccination in the near future, mean intent scores were 
significantly higher following receipt of an HPV information leaflet. The present study 
assessed mothers’ intent to vaccinate daughters against HPV in the future, and found no 
significant difference in future intent to vaccinate for HPV between groups, indicating 
that mothers whose daughters have survived cancer intended to vaccinate their child 
against HPV at similar rates as mothers of healthy daughters. Consideration should be 
made of the fact that mothers of healthy control daughters were recruited as an 
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acquaintance sample, and were therefore familiar with the participants in the comparison 
group. It is possible that mothers in both groups have similar attitudes toward HPV 
vaccination and even those whose daughters receive medical care from providers in their 
home community, where HPV vaccinations may be readily available, have decided not to 
vaccinate their daughters as of yet. It is important to note that the mean response for 
intentions was between ‘Not Sure’ and ‘Likely,’ indicating that, on average, most 
mothers are somewhat undecided or are leaning towards potentially vaccinating 
daughters in the future. 
The advancements in the treatment of childhood cancer have resulted in survivors 
living well into adulthood. Given that the median age of cervical cancer diagnosis is 
between 47 to 48 years-of-age and that childhood cancer survivors are at increased risk 
for persistent HPV infection, there is a need to better understand factors which influence 
vaccination intent and to assess for factors that may improve HPV vaccination rates 
among survivors. The present study compared all participating mothers in cancer  and 
control groups for differences on medical and demographic factors, cervical cancer/HPV 
knowledge, health beliefs, and self-efficacy because these variables had yet to be 
examined, but may have important implications, among survivors of childhood cancer. 
In general, few differences between cancer and control groups emerged, 
indicating that the acquaintance control sample successfully recruited mothers of similar 
demographic backgrounds to the mothers of cancer survivors. Results also indicated that 
the two groups were not significantly different with respect to maternal medical care. 
Although no significant difference was found between groups on HPV-related knowledge 
scores, participating mothers were relatively unknowledgeable regarding HPV and HPV-
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related health risks, as mean knowledge levels were fairly low. Previous published 
reports have also demonstrated low levels of HPV knowledge among women (Allen et 
al., 2009). No differences were found between groups with regard to Health Belief factors 
including perceived barriers to HPV vaccination, perceived benefits to HPV vaccination 
for their daughters, or mothers’ self-efficacy to vaccinate daughters. 
There were some notable differences between groups of mothers. Specifically, the 
number of white and minority participants in the cancer and control groups differed 
significantly. Although the survivorship group included significantly more ethnic 
minority mothers than the healthy control group, the distribution of children diagnosed 
with cancer was consistent with the US population. Results also indicated that groups 
differed based on perceived susceptibility as well as severity. Mothers of cancer survivors 
rated their daughters as more vulnerable to HPV-related health risks than mothers of 
healthy control daughters, yet indicated less severity for HPV and related health risks for 
their daughters than mothers of healthy daughters. In other words, mothers whose 
daughters survived childhood cancer believed that their daughters were more likely to 
contract an HPV infection than healthy daughters; however, they also believed HPV 
infection to be less severe or pose fewer health consequences to their daughter than 
mothers of healthy daughters. This finding may be explained by the fact that survivors of 
childhood cancers are indeed at an increased risk for HPV infection due to 
immunosuppression, and mothers of survivors are perhaps aware that their daughter’s 
compromised immune system places them at higher risk for infections. 
Mothers of childhood cancer survivors may also worry that their daughters will 
develop a second malignancy. Recently published findings from the Childhood Cancer 
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Survivor Study (CCSS) indicate that survivors of childhood cancer maintain a nearly 1 in 
10 chance of developing a subsequent neoplasm, and those surviving the first subsequent 
neoplasm remain at risk for development of multiple subsequent neoplasms (Armstrong 
et al., 2011). It is possible that survivors’ mothers received messages from oncologists 
stating that their daughter is more susceptible to contracting illnesses than healthy peers 
and HPV infections specifically. Families may gain firsthand experience living with 
immunocompromise during treatment for cancer, as it is not uncommon that patients are 
required to wear protective masks in order to attend school or interact with peers. This 
may also contribute to increased perceptions of susceptibility to infectious disease. 
Other factors specific to HPV and STI’s may also contribute to the finding that 
mothers of survivors rated their daughters as more susceptible to HPV than mothers of 
healthy controls. For example, mothers of cancer survivors may be more aware of the fact 
that HPV is the most common sexually transmitted infection or may have a family history 
of HPV and/or cervical cancer. It is also possible that mothers of survivors maintain 
perceptions of their daughter’s sexual behavior which place their daughter at increased 
risk for contracting HPV or perhaps their daughter has already been diagnosed with an 
HPV infection. 
Less perceived severity for HPV and HPV-related health risks for childhood 
cancer survivors may be explained as mothers viewing cancer diagnosis and treatment as 
the greatest health risk for their daughters and that HPV infection is less severe in 
comparison. In other words, mothers of survivors may have lower HPV-related severity 
scores due to an overall sense of perceived invulnerability or resiliency – even if their 
daughter contracts an HPV infection, she has successfully conquered cancer once before, 
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so HPV is a much less frightening diagnosis and less daunting to treat. A sense of 
resiliency in adolescent cancer survivors has been related to quality of decision-making 
for risk behaviors (Hollen, Hobbie, Finley, & Hiebert, 2001). Mothers who believe that 
their daughter will not engage in risky sexual behavior may also endorse less perceived 
severity related to HPV infection. These mothers may already hold the belief that their 
daughter’s cancer diagnosis poses serious medical and social repercussions, therefore any 
consequences related to HPV infection may seem more tolerable. If mothers of childhood 
cancer survivors are unacquainted with anyone with a personal history of HPV infection 
or cervical cancer, it is possible that these mothers are also unaware of the consequences 
related to HPV infections. It is also possible that mothers of survivors are indeed unaware 
of the link between HPV and cervical cancer, or perhaps are aware that many women are 
able to clear an HPV infection without serious consequences. 
Additionally, survivors of childhood cancer are now living longer and the median 
age of CCSS participants is 32 years-of-age, meaning that many have yet to reach an age 
when cancer rates begin to rise in the general population (Armstrong et al., 2011), 
particularly given that the median age for cervical cancer expression is 48 years. 
Consequently, survivor specialists may not be educating their patients on their risk for 
cervical cancer, as this has yet to be demonstrated among survivors despite the research 
demonstrating their increased risk for HPV-related complications. Unfortunately, given 
that childhood cancer survivors are at increased risk for HPV infection and related 
complications, their inability to clear an HPV infection may actually pose HPV health 
concerns of greater severity. As cervical cancer is one of a select group of cancers for 
which risk reduction could occur by behavioral means (e.g., reducing risky sexual 
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behavior and completing in HPV vaccination), survivors may be able to alter their risk 
for future HPV-related complication. 
Further analyses revealed that, of vaccine naïve daughters, future intent to 
vaccinate was correlated with daughter’s age, perceived severity, perceived barriers, 
perceived benefits, and self-efficacy. All correlations were in the expected directions; 
intent was negatively correlated with daughter’s age and perceived barriers, and 
positively correlated with perceived severity, benefits, and self-efficacy. Mothers with 
younger daughters and those who endorsed greater perceived severity of HPV infection, 
fewer perceived barriers to vaccination, greater perceived benefits to vaccination, and 
higher levels of self-efficacy had greater intent to vaccinate their daughters against HPV 
in the future. 
Previous literature has indicated that daughter’s age is related to HPV vaccination 
intent; however, unlike in the present study, Reiter and colleagues (2010) demonstrated 
older age of daughter to be related to intent to vaccinate in the future. Furthermore, 
researchers have also found no differences in intent to vaccinate by daughter’s age group 
(Gottlieb et al., 2009). Several hypotheses have been developed in interpreting this 
finding herewithin specific to the inverse relationship between age and vaccination intent. 
Of note, the cited studies measured daughter’s age as a categorical variable (i.e., 10 to 12 
years, 13 to 15 years, and 16 to 17 or 18 years of age), whereas the present study 
measures daughter’s age as a continuous variable (9 to 17 years of age). All daughters of 
participating mothers were of eligible age to receive the vaccine. Mothers with younger 
daughters may have endorsed higher intent to vaccinate in the future because there will 
be time for additional studies to evaluate the safety and efficacy of the relatively new 
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immunization before their daughter ages out of the recommended window for 
vaccination. As the HPV vaccine becomes more widely marketed, it is likely that mothers 
with younger daughters have been exposed to more cues to action for the vaccine series 
during the timeframe when their daughter is within the recommended age range for 
vaccination; perhaps older daughters did not receive key vaccination messages from their 
physicians during their preadolescent years when the vaccine was first available, and 
have now “aged out” of the 12-13 year age range which is ideal for vaccination. 
Additionally, it is possible that the relation between intent to vaccinate and 
daughter’s age is mediated by perceptions of daughter’s sexual activity. Mothers may be 
confident that younger daughters are not yet sexually active and would therefore benefit 
from vaccination; whereas mothers with older daughters may deem vaccination 
unnecessary if their daughters are currently sexually active and likely to already have 
been exposed to HPV. This should be further examined in future studies. Mothers with 
older daughters may require additional educational information regarding the importance 
of vaccinating females prior to the onset of sexual activity in order to achieve greatest 
protection. Mothers may also benefit from reminders that even if their daughters are 
sexually active, it is unlikely that they have been exposed to all 4 strains of HPV against 
which Gardasil protects. 
The inverse relation between daughter’s age and intent to vaccinate may also be 
explained by a developmental shift in responsibility for medical care. Younger daughters   
may still receive regular medical care from pediatricians who have likely discussed the 
HPV vaccine with the patient’s family. As age increases, so does an adolescent’s input 
into her medical care (Humiston & Rosenthal, 2005). With regard to the familial 
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decision-making process for children’s healthcare, mothers maintain a certain sense of 
influence over younger daughters’ medical care; whereas more negotiating may be 
required to convince an older adolescent to provide vaccination assent to initiate and 
complete the vaccine series. Furthermore, as children grow older, they are less likely to 
attend medical appointments (Ziv, Boulet, & Slap, 1999) and it is possible that older 
adolescents are beginning to be seen individually by their primary care physician for 
behavioral risk counseling, such that their parent does not have the opportunity to hear 
immunization messages from the physician. 
The present study’s findings are similar to previous research correlating Health 
Belief factors to intent (Gerend et al., 2007; Juraskova et al., 2011; Kahn et al., 2008), 
and nearly all health belief factors were included into the regression model. Mothers in 
the present study were more likely to intend to vaccinate daughters against HPV if they 
held higher beliefs in the severity of HPV infections. This implies that information 
regarding the serious health risks that persistent HPV infection poses for their daughter 
could be emphasized further in order to encourage mothers to vaccinate their daughters, a 
notion especially important to consider for the high risk cancer sample. Furthermore, 
when mothers perceived fewer obstacles to obtaining HPV immunizations, they were 
more likely to intend to vaccinate daughters in the future. 
Mothers were more likely to endorse higher levels of intent to vaccinate in the 
future if their perception was that HPV immunization offers protective health benefits for 
their daughter. Mothers with higher perceived benefits to HPV immunization may also 
hold a belief in the health protection offered by immunizations in general. When 
examining individual benefits of the vaccine, mothers rated a reduction in the chance of 
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their daughter getting cervical cancer as the greatest benefit, so it may be that mothers 
with greater intent to vaccinate daughters also desire to engage behaviors which support a 
public health effort to reduce cancers in women. Perceived benefits have previously been 
reported as the strongest predictor of HPV vaccine acceptability (de Visser & 
McDonnell, 2008; Dempsey et al., 2006), and findings from the present study 
substantiate such reports as regression analyses revealed perceived benefits to have the 
greatest beta weight among predictors of future HPV vaccination intent. 
Similarly, when mothers endorse greater self-efficacy and believe they have the 
means and are able to successfully vaccinate their child, they are more likely to intend to 
immunize their daughter against HPV in the future. These findings continue to support 
the notion that public health efforts and health care providers should focus on addressing 
the concerns that mothers have regarding the safety and efficacy of the HPV 
immunization while emphasizing the potential health benefits to protecting  their 
daughters from the serious types of HPV (Dempsey, Abraham, Dalton, & Ruffin, 2009; 
Tissot et al., 2007). 
Previous studies have demonstrated that strong physician recommendation of the 
HPV immunization is related to maternal acceptance of the vaccine (Dempsey et al., 
2009) and that physician recommendation is correlated with vaccine uptake (Gerend et 
al., 2009; Reiter, Brewer, Gottlieb, McRee, & Smith, 2009). In the present study, 
however, physician recommendation was not found to correlate with future intent to 
vaccinate. Perhaps more importantly, fewer than half of all mothers endorsed that their 
daughter’s physician had recommended HPV vaccination, despite indicating that their 
daughters have received all recommended childhood vaccines. It may be that without a 
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medical provider’s suggestion to immunize their daughter, mothers are unaware of the 
recommendation that all females receive the vaccine series. In order to enhance 
vaccination among childhood cancer survivors, medical providers will need to address 
the importance of HPV immunization in this population. Although the current study did 
not examine this specifically, it is possible that some mothers received a recommendation 
from their daughter’s physician and yet did not vaccinate. Future efforts are needed to 
examine differences in those mothers who did/did not receive a vaccine recommendation 
and those who did/did not have daughter vaccinated. Such efforts may identify the best 
strategy for physicians to utilize when recommending HPV vaccination to mothers in 
order to increase the likelihood that they will adhere to the recommendation. 
When controlling for daughter’s age and daughter’s history of cancer (i.e., 
childhood cancer survivor or healthy control), a hierarchical linear regression analysis 
revealed that younger age and perceptions of increased vaccine benefit uniquely 
predicted intent to vaccinate daughters. When predictors were examined separately for 
mothers of cancer survivors and mothers of healthy daughters, no group differences 
emerged, indicating that factors which influence mothers’ intent to vaccinate healthy 
daughters appear to be the same for mothers of adolescent survivors of childhood cancer. 
Given that age and perceived benefits were unique predictors of intent, future 
interventions aimed at increasing HPV vaccination among the general population as well 
as among cancer survivors should seek to highlight the benefits of HPV vaccination, 
particularly for older, sexually naïve females. For survivors of childhood cancer, this may 
potentially be done during medical visits with her oncologist. It is important for health 
care providers to assess mothers’ perceived benefits to HPV vaccination, and seek to 
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provide mothers with factual information regarding HPV immunization 
recommendations. Physicians are often unable to spend a great length of time with any 
one patient and/or family and may turn to clinical psychologists and other health care 
providers, trained in motivational interviewing, to assist mothers in creating discrepancy 
and resolving any ambivalence regarding vaccinating daughters against HPV. 
When interpreting these findings, one should consider the study’s limitations. As 
in other cross-sectional study designs, only associations, not causalities, can be 
determined between medical, demographic, and health belief factors and intent. Due to 
the small sample of this study, results should be interpreted with caution, and future 
studies should seek to enroll higher numbers of participants, as there may be advantages 
to having a larger control sample of healthy daughters. Larger sample sizes will provide 
future studies with greater power to detect differences among groups of healthy females 
and those with a history of childhood cancer, and findings will have greater 
generalizability. By recruiting a control group of acquaintance mothers, regional 
differences in vaccination rates could not be accounted for. Vaccination coverage for 13-
17 year old adolescents has been shown to vary by state (Centers for Disease Control and 
Prevention, 2010b). Institutional review board approval for the present study placed great 
emphasis on participant confidentiality and therefore data were not collected with regard 
to the control  participants’ state of residence; however, given that all demographic 
variables save for ethnicity were found to be consistent between groups, this is perhaps 
less of a concern for the present study. Future studies may wish to consider examining 
regional differences in vaccination rates. 
 
46 
Additionally, all cancer participants were recruited from a single site. Findings 
may not generalize to other pediatric cancer survivors or healthy daughters not 
acquainted with a childhood cancer survivor. It is important to note that an emphasis is 
placed on research at the recruitment institution used for the present study, and families 
of childhood cancer survivors are accustom to completing study questionnaires as part of 
their annual visit. There may be potential differences in HPV vaccination completion and 
intent between mothers of cancer survivors who did and did not complete this study, 
among mothers whose daughters receive oncology care at different institutions, and even 
among survivors of differing cancer diagnoses. This study highlights the importance of 
recruiting control samples of healthy females from the general population in order to 
further examine differences in intent to vaccinate between survivors and the general 
population. 
Methodological issues, such as the way intent was measured, may not have 
allowed significant associations to emerge. The purpose behind measuring intent with 
four items was to also gather data related to mothers’ readiness to engage in vaccination; 
however, there appeared to be some confusion in questionnaire instructions, as many 
mothers did not complete all four intention items. Because a total intent sum score could 
not be calculated for all participating mothers with vaccine naïve daughters, the decision 
was made to use only the final intent item to measure ‘future’ intent. Mothers who 
reported higher intentions to vaccinate daughters within the next month to year were 
excluded in this process, thereby possibly deflating actual vaccine intentions. For 
example, a mother may have endorsed that she is ‘Very Likely’ to have her daughter 
vaccinated within the next month and ‘Definitely Will’ vaccinate her daughter within the 
 
47 
next 6 months, but then failed to complete the final two intent items. As a result, her data 
were not included in the final analyses, although she endorsed high intent to vaccinate her 
daughter.  
Several improvements should be made for future studies examining HPV 
vaccination among survivors of childhood cancer. A longitudinal study design 
reassessing vaccination rates among survivors and important factors related to vaccine 
intent over time would be beneficial given that HPV vaccination rates and attitudes have 
not been assessed among families of childhood cancer survivors until now. Such a design 
would also monitor for changes in attitudes toward vaccination and vaccine uptake within 
this population. Future studies should also strive for larger sample sizes with more 
equivalent numbers of participants in survivorship and control samples. 
Comparisons between survivors and healthy adolescent females may continue to 
be monitored for any differences that may arise. Future studies should continue to 
examine the predictive nature of the factors included in the conceptual model examined 
in the present study on intent as well as vaccine initiation and completion. Such studies 
should also examine the predictive nature of additional factors not included in the present 
study (i.e., cues to action, socioenvironmental factors, sexual communication, time since 
diagnosis, as well as treatment intensity) on intent to vaccinate for HPV, as well as 
engagement in immunization. Additionally, relations between vaccine intentions and 
engagement in vaccine initiation and completion will need to be examined among 
childhood cancer survivors.   
Mothers’ perceptions of daughters’ sexual behavior may be a key factor to assess 
in future studies, as well; as such perceptions may influence mothers’ intent to vaccinate 
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daughters against STI’s. Similarly, communication between mothers and daughters in 
general, with regard to sexual topics, and with regard to HPV and cervical cancer 
specifically should be assessed for its role in vaccinating adolescent females against 
HPV. 
Future studies may also evaluate the utility of providing mothers with an HPV 
information sheet. Providing mothers with factual knowledge regarding HPV health risks 
and immunization may influence intentions for vaccinating daughters against HPV in the 
future. Mothers can share the fact sheet with partners and significant others, which in turn 
may increase the likelihood of discussion of vaccination within partnerships and families. 
Adjusting for time since vaccine licensure, it is necessary to test the efficacy of a 
knowledge intervention. Future interventions aimed at increasing HPV vaccination rates 
among childhood cancer survivors may seek to provide the HPV vaccine series at 
pediatric oncology centers for patients who are able to return to clinic for the 3 shot 
series. Medical providers at such institutions may also coordinate care with medical 
providers at local health care facilities for patient families who are unable to return for 
the series of injections. 
To further our knowledge base, vaccination intent should be measured in ways 
such that more participant data are eligible for inclusion in the analyses. Future studies 
should strive to clarify that all items are to be answered, simplify the measurement of 
intent by simply assessing future intent with one item, or perhaps utilize the collected 
data in a more meaningful way by examining associations of varying levels of intent. The 




As mentioned previously, the literature is beginning to address the increased risk 
of HPV related complications among childhood cancer survivors, necessitating additional 
research to demonstrate increased rates of cervical cancer in survivors of childhood 
cancer as the cohort of survivors reaches ages when cancer rates begin to rise in the 
general population. At present, there is a paucity of research establishing the 
immunogenicity of the HPV vaccination among immunocompromised populations. In 
HIV-infected children, differences have been noted in quadrivalent HPV vaccine 
seroconversion, as titers against HPV subtypes 6 and 18 were demonstrated to be 30-50% 
lower than age matched controls (Garland et al., 2007; Levin et al., 2010) A Phase II 
study is warranted to examine the safety, immunogenicity, and tolerability as well as 
scheduling and dosage of the HPV vaccine among childhood cancer survivors. 
In conclusion, findings of the current study further our understanding of familial 
decision-making about child and adolescent health through identification of factors 
influencing HPV vaccination among female survivors of childhood cancer and healthy 
controls. Future interventions designed to increase HPV vaccination among childhood 
cancer survivors may draw upon the study findings to enhance immunization rates and 
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Figure 3. Enrollment report for mothers of healthy control daughters. 
Note. a Fifty-four eligible controls pending due to on-going attempts to contact for 

















































Variables Studied in HPV Questionnaire 




# of items in 
scale 
Health belief factors pp. 71-73 Cox et al., 2010 
Dempsey et al., 
2006 
Gerend et al., 
2007 






Mothers’ self-efficacy p. 73  6 












Dempsey et al., 
2006 










Vaccination status p. 69  Maternal: 1 
Daughter: 1 


























t(195) = 0.37, p = 0.71
t(195) = 0.66, p = 0.95
Maternal education 3.22 (1.41) 3.48 (1.13) t(184) = 1.07, p = 0.29
Annual income 5.82 (4.33) 7.17 (4.12) t(182) = 1.78, p = 0.08
HPV knowledge 6.04 (1.65) 6.43 (1.59) t(195) = 1.40, p = 0.16
Susceptibility 11.82 (4.72) 9.61 (3.86) t(181) = -2.75*, p = 0.007
Severity 31.82 (5.25) 34.76 (4.78) t(181) = 3.25*, p = 0.001
Barriers 24.63 (5.92) 24.95 (6.44) t(176) = 0.31, p = 0.76
Benefits 23.44 (4.21) 23.67 (4.36) t(178) = 0.32, p = 0.75
Self-efficacy 25.78 (3.94) 26.51 (3.83) t(185) = 1.07, p = 0.29
Vaccination intent 3.56 (1.80) 3.94 (2.03) t(118) = 0.96, p = 0.34
Note. HPV = human papillomavirus. 
Characteristics measured as continuous variables. 










N = 153 
Mothers of 
Controls 
N = 44  
Statistical test
p-value
Ethnicitya   χ2(1) = 4.25*
White 116 (75.8) 39 (88.6) p = 0.04
Minority 36 (23.5) 4 (9.1) 
Marital statusb   χ2(2) = 4.57
Married 109 (71.2) 36 (81.8) p = 0.10
Wid/div/sep 22 (14.4) 7 (15.9) 
Other 21 (13.7) 1 (2.3) 
Vaccine statusc   χ2 (1) = 0.25
Vaccinated 50 (32.7) 13 (29.5) p = 0.62
Not vaccinated 99 (64.7) 31 (70.5) 
Annual Pap testd   χ2(1) = 1.01
Yes 105 (68.6) 35 (79.5) p = 0.31











Table 3 (continued) 





N = 153 
Mothers of 
Controls 







Yes 60 (39.2) 22 (50.0) p = 0.24
 No 86 (56.2) 21 (47.7) 
STId   χ2(1) = .25
     Yes 22 (14.4) 8 (18.2) p = 0.62
     No 124 (81.0) 36 (81.8) 
HPV infectiond   χ2(1) = 0.001
     Yes 10 (6.5) 3 (6.8) p = 0.98
     No 128 (83.7) 39 (88.6) 
Cervical cancerd   χ2(1) = 0.76
     Yes 8 (5.2) 1 (2.3) p = 0.38





     Yes 141 (92.2) 44 (100) p = 0.21





Table 3 (continued) 





N = 153 
Mothers of 
Controls 
N = 44  
Statistical test
p-value




     Yes 67 (43.8) 21 (47.7) p = 0.99
     No 73 (47.7) 23 (52.3) 
Note. STI = sexually transmitted infection; HPV = human papillomavirus; Rec = 
recommendation. 
Characteristics measured as categorical variables. 
a0 = minority, 1 = white; b0 = widowed/divorced/separated, 1 = married, 2 = other; c0 = not 






Correlations among Study Measures 
Variable 1 2 3 4 5 6 7 8 9 10 11 12 13 
1. Intent              
2. Knowledge -0.03             
3. Susceptibility  0.06  0.02            
4.  Severity  0.29**  0.19  0.12           
5.  Barriers -0.34** -0.15  0.05 -0.15          
6.  Benefits  0.54**  0.14  0.02  0.25* -0.48**         
7. Self-efficacy  0.25*  0.11  0.33**  0.40** -0.39**  0.26*        
8. Annual Pap  0.02 -0.09  0.09  0.11  0.05  0.04  0.04       
9. Abnormal Pap results  0.19 -0.16  0.02 -0.04 -0.03  0.08 -0.19  0.13      
10. STI -0.06  0.02 -0.00  0.08  0.22* -0.31** -0.06  0.07  0.14     
11. HPV infection  0.05  0.26*  0.10 -0.07  0.10 -0.01 -0.13  0.01  0.41**  0.08    
12. Cervical cancer  0.09  0.20  0.11 -0.17  0.13 -0.10 -0.05 -0.01  0.27*  0.07  0.47**   
13. Daughter immunizations  0.15  0.16  0.02  0.00 -0.09 -0.02  0.09  0.01  0.19 -0.07  0.08  0.05  
14. Physician rec HPV vacc  0.18  0.29* -0.01  0.29** -0.09  0.14  0.23* -0.18 -0.12  0.38** -0.03 -0.01 0.01 
 
72 
Note. N = 84. STI = sexually transmitted infection; HPV = human papillomavirus; Rec = recommendation; Vacc = vaccine. 





Regression Analysis for Variables Predicting Intent to Vaccinate Daughter for HPV in 
the Future 
Predictive factors β t Sig. (p) 
Groupa -0.14 -1.44 .15 
Daughter’s age -0.18 -1.98 .05* 
Perceived severity 0.12 1.08 .29 
Perceived barriers -0.09 -0.80 .43 
Benefits 0.41 3.89 <.001** 
Self-efficacy 0.05 0.42 .67 
Note: N = 84 
a0 = mother of healthy control, 1 = mother of cancer survivor. 
*p ≤ .05. **p ≤ .01. 
R2 = .374 








You are being invited to take part in a research study about a family’s decision to have 
their daughters vaccinated against the virus that causes cervical and other cancers. This 
virus is known as the human papillomavirus or HPV. A goal of the study is to better 
understand what parents know about cervical cancer risk and what factors are important 
in their vaccination decisions.  
 
As part of the study, you will be asked to fill out this questionnaire. Completion should 
take about 15 minutes.  
 
It is entirely up to you whether you decide to take part in this study.  If you decide not to 
take part in the study, this decision will not affect your daughter’s care at St. Jude.  If you 
decide to participate, please fill out the questionnaire on your own, in private. You are 
free to answer all, some, or none of the questions. You may feel some discomfort while 
answering some questions related to HPV, cervical cancer, and other women’s health 
issues. Please remember that your answers will be kept private and will not be shared 
with your daughter’s medical team. Do NOT put any additional information on the 
questionnaire (such as name, date of birth, home address, zip code, or phone number). 
Only the participant identification number will be used to link your responses with your 
daughter’s medical information. After completing the questionnaire, place it in the 
attached envelope. Seal the envelope and give it to a member of our study team. If you 
are completing this questionnaire away from the St. Jude campus, please place the 
stamped self-addressed envelope into the mail. Thank you in advance for your 






Date Form Completed: __________________
    (today’s date)  
  
 
Please answer the questions below. When lettered options are provided, please circle 




1. How old are you (in years)? ____________ 
 
 
2. What is your Race/Ethnicity? (circle only one response) 
 
1) Asian or Pacific Islander 
2) Black/African American 
3) Caucasian 
4) Hispanic/Latino 
5) Native American 
6) Middle Eastern 
7) Biracial or Multiracial - Please 
specify: _________________ 
8) Other - Please specify: 
_____________________
 





4) Living with a partner, not married 
5) Single, never married, dating 
6) Single, never married, not dating 
7) Other - Please specify: ________________________________________ 
 















14) Episcopalian  




5. Please indicate the number of years of education you have completed. 
1) Grade school – last grade you completed: ________ 
2) Some High School – last grade completed: ________ 
3) High School Diploma or GED 
4) Some college – # of years in college: ________ 
5) Bachelor’s Degree 
6) Some graduate work – # of years post college: ________ 
7) Graduate Degree 




6. What was your annual household income last year? 
1) 0 - $9,999  
2) $10,000 - $19,999  
3) $20,000 - $29,999  
4) $30,000 - $39,999  
5) $40,000 - $49,999   
6) $50,000 - $59,999 
7) $60,000 - $69,999  
8) $70,000 - $79,999  
9) $80,000 - $89,999  
10)  $90,000 - $99,999  
11)  $100,000 - $109,999  
12)  $110,000 - $119,999  
13)  $120,000 - $129,999  
14)  $130,000 - $139,999  
15)  $140,000 - $149,999  
16)  More than $150,000  
 
 
You are a caregiver for a girl who is between 9 and 17 years old. For the remainder of 
this questionnaire, she will be referred to as your “daughter”. If your daughter is followed 
in the ACT (survivorship) clinic, please answer all questions about your daughter who 
is the St. Jude patient.  If you do not have a daughter seen in the ACT clinic at St. Jude, 
and you have more than one daughter between the ages of 9 and17, please answer all 
questions about your daughter who is closest in age to the St. Jude patient who referred 
you to this study. 
 
7. What is your relationship to her? (circle only one) 
1) Biological Mother 
2) Stepmother 
3) Adoptive Mother 
4) Grandmother 
5) Aunt 
6) Foster Mother 
7) Other - Please specify: ________________________________________ 
 
 
8. How old is your daughter (in years)?: _______________________________ 
 
 





We would like to evaluate your current level of knowledge regarding specific health 
topics of importance to women and their families. Please circle the number of the correct 
response to each item below. If you are unsure about the correct answer, please give us 
your best guess. Mark only one answer per question. 
 
1. The main job of a Pap smear is to screen for _____________. 
 
1) Diabetes 
2) Ovarian cancer 
3) Heart disease 
4) Cervical cancer 
 
2. _______ can cause abnormal Pap smear results. 
 
1) Increased caffeine 
2) HPV infection 
3) High cholesterol 
4) Urinary tract infection 
 
3. Which of the following increases your chances for getting an HPV-related cancer? 
 
1) Smoking cigarettes 
2) Giving birth to many children 
3) Having first sex at a young age 
4) All of the above 
 
4. Which of the following is associated with increased risk for Human Papillomavirus 
(HPV) infection? 
 
1) Having had multiple sexual partners 
2) Drinking after someone else 
3) Having sex more than once a day 
4) Engaging in same sex (e.g., gay or lesbian) activities 
 
5. How common are HPV infections? 
 
1) Almost no one gets it, HPV is a very rare infection 
2) One-fourth of sexually active people contract HPV in their lifetime 
3) One-half of sexually active people contract HPV in their lifetime 








1) 14 to 24 years 
2) 25 to 35 years 
3) 36 to 46 years 
4) 47 to 57 years 
 
7. How is HPV spread? 
 
1) Oral – genital contact 
2) Digital (finger) – genital contact 
3) Genital – genital contact 
4) All of the above 
 
8. HPV is the main cause of _____________. 
 
1) Pregnancy 
2) Genital warts 
3) Kidney stones 
4) Herpes 
 
9. HPV infections can be cured by ____________. 
 
1) Antibiotics 
2) Steroid shots 
3) Aspirin 
4) There is no cure for HPV infection. 
 









Vaccination and Vaccine Intent 
 
Now we would like to continue asking you about health topics that are important to 
women and their families. There are no right or wrong answers to the following 
questions. We would like to know what you think about these important topics. Mark 
your response(s) to each item below. 
 





c) Not Sure 
 
2. Where did you learn about the HPV vaccine? (choose all that apply) 
 




e) School teacher 
f) Spouse 
g) Relative 
h) TV Commercials 
i) Internet 
j)  Church 
k)  Insurance company 
l) Other - Please specify: 
________________________ 
 




3) Not Sure 
 
2. Has your daughter received the HPV vaccination (Gardasil or Cervarix)? Mark only 
one answer. 
 
My daughter has received… 
1) 0 of the 3 shot series (has not started the vaccine) 
2) 1 of the 3 shot series 
3) 2 of the 3 shot series 









3. If your daughter has NOT already started the HPV vaccination series, please answer the following 
questions: 
 



















a. start the HPV vaccine 
















b. start the HPV vaccine 
















c. start the HPV vaccine 








































1. Please rate the likelihood of the following statements: 
 


















a. to get an HPV infection? 1 2 3 4 5 
b. to have an abnormal Pap test? 1 2 3 4 5 
c. to get cervical cancer? 1 2 3 4 5 
d. to get a HPV-related cancer other than 
cervical cancer? 
1 2 3 4 5 
e. to die from cervical cancer? 1 2 3 4 5 















a. HPV can cause cervical cancer. 1 2 3 4 5 
b. Infection with HPV can lead to a serious 
illness. 
1 2 3 4 5 
c. HPV infection can cause genital warts. 1 2 3 4 5 
d. Women can die from getting infected with 
HPV. 
1 2 3 4 5 
e. Treatment for cervical cancer is difficult. 1 2 3 4 5 
f. Getting cervical cancer would affect my 
daughter’s future (ability to have children, 
sexual functioning, disability). 
1 2 3 4 5 
g. Getting HPV would result in social 
consequences for my daughter (having to 
tell sexual partners, parents, health care 
workers, insurance companies, etc.) 
1 2 3 4 5 
h. Getting HPV would make it difficult for 
my daughter to get a husband/partner. 
1 2 3 4 5 


















a. It would be hard for me to find the time to 
get my daughter vaccinated for HPV. 
1 2 3 4 5 
b. It would be hard for me to take my 
daughter to a clinic or doctor 3 times to get 
completely vaccinated for HPV. 
1 2 3 4 5 
c. It would be hard for me to get 
transportation to take my daughter for 
more than one appointment to get 
vaccinated for HPV. 
1 2 3 4 5 
d. It would be easy to take my daughter to 
the doctor’s office to get the 3-shots of the 
HPV vaccine. 
1 2 3 4 5 
e. My daughter experiences pain when she 
receives a vaccination shot. 
1 2 3 4 5 
f. My daughter is in danger when she 
receives a vaccination shot. 
1 2 3 4 5 
g. The HPV vaccine would encourage my 
child to be more sexually active. 
1 2 3 4 5 
h. Not enough research has been completed 
on the safety of the HPV vaccine. 
1 2 3 4 5 
i. Not enough research has been completed 
on the effectiveness of the HPV vaccine. 
1 2 3 4 5 
j. I do not believe in vaccinations. 1 2 3 4 5 
k. The HPV vaccine is expensive. 1 2 3 4 5 
l. Having my daughter vaccinated for HPV 
is against my religious beliefs. 
1 2 3 4 5 















a. The HPV vaccine is very effective in 
preventing cervical cancer. 
1 2 3 4 5 
b. The HPV vaccine would greatly reduce the 
chance of getting cervical cancer. 
1 2 3 4 5 





d. The HPV vaccine is very risky. 1 2 3 4 5 
e. Getting the HPV vaccine reduces worry about 
sexually transmitted infections. 
1 2 3 4 5 
f. Getting the HPV vaccine reduces worry about 
developing cervical and other HPV-related 
cancers. 
1 2 3 4 5 
g. Getting my daughter the HPV vaccine 
did/would help me to feel like a good parent. 
1 2 3 4 5 
Please rate how much you agree or disagree with the following statements:  
 

















1. talk with my daughter’s doctor about this 
issue. 
1 2 3 4 5 
2. discuss this vaccine with my daughter. 1 2 3 4 5 
3. discuss this vaccine with my spouse/partner. 1 2 3 4 5 
4. pay (or get insurance to pay) for the vaccine. 1 2 3 4 5 
5. get my daughter to the medical clinic. 1 2 3 4 5 
6. successfully negotiate completion of the HPV 
vaccination with my daughter. 
1 2 3 4 5 
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Are there other things which did/would influence your ability to get your daughter 








 Social and Environmental Influences on Decisions 
 
There are new vaccines that protect against HPV types that cause most cervical cancers. 
Some families decide to have their adolescent daughters vaccinated, while others decide 
not to. The choice for each family is personal and many different things may influence 
the decision. Please answer the following questions so we can better understand how the 
decision to vaccinate for HPV is made. 
 
Please answer the following items regardless of whether or not your daughter has been vaccinated.  
Please rate how important the following factors were/would be in making HPV vaccine decisions for 




















1. Physician recommendation 1 2 3 4 5 
2. TV commercials/media 1 2 3 4 5 
3. Family history of abnormal Pap smears 1 2 3 4 5 
4. You or anyone close to you having 
experienced genital warts 
1 2 3 4 5 
5. Family history of cervical cancer 1 2 3 4 5 
6. Family history of cancer in general 1 2 3 4 5 
7. You or anyone close to you having 
experienced a sexually transmitted 
infection 
1 2 3 4 5 
8. Your friends’ approval of the HPV 
vaccine 
1 2 3 4 5 
9. Your friends having their daughters 
vaccinated for HPV 
1 2 3 4 5 
10. Required for school enrollment 1 2 3 4 5 
11. Spouse/significant other’s approval of 
the HPV vaccine 
1 2 3 4 5 
12. Your religious beliefs 1 2 3 4 5 
13. Insurance coverage/cost 1 2 3 4 5 
14. Other (please specify): 
__________________________________
__________________________________







1. Does your health insurance cover the HPV vaccination? 
1) Yes 
2) No 
3) Not Sure 
4) I do not have health insurance 
 
























1. Please rate how much you agree or disagree with the following statements: 
 














a. Mother only 1 2 3 4 5 
b. Father/spouse/partner only 1 2 3 4 5 
c. Daughter only 1 2 3 4 5 
d. Parents decide without daughter’s 
input 
1 2 3 4 5 
e. Parents decide with daughter’s 
input 
1 2 3 4 5 
f. Doctors should decide 1 2 3 4 5 
g. Schools should decide 1 2 3 4 5 
h. Government should decide 1 2 3 4 5 
i. Church should decide 1 2 3 4 5 
j. Other - Please specify: 
_______________________________
_________________________ 





As girls mature, they may begin to visit a doctor specializing in the female reproductive 
system. This type of doctor is known as a “gynecologist” or an 
“obstetrician/gynecologist,” sometimes known as an OB/GYN. There are many reasons 
why females visit these doctors, and by filling out this section, you will help us estimate 
how many women are getting screened/tested for cervical cancer, how often 
screening/testing is taking place, and even the results of screening/testing. By knowing 
this information, we can maximize our chances to help women stay healthy in the future. 
 
The following questions are about YOUR personal medical history.  Please circle your 
item responses below. 
 
1. Have you ever been to an obstetrician/gynecologist (OB/GYN)? 
1) Yes 
2) No 
3) Not Sure 
 
2. Have you ever gotten a mammogram? 
1) Yes 
2) No 
3) Not Sure 
 
3. Do you get a Pap test every year? 
1) Yes 
2) No 
3) Not Sure 
 
4. Have you ever had an abnormal Pap test result? 
1) Yes 
2) No 
3) Not Sure 
 
5. Have you ever had a sexually transmitted infection (STI)? 
1) Yes 
2) No 
3) Not Sure 
 
6. Have you ever had an HPV infection? 
1) Yes 
2) No 
3) Not Sure 
 





3) Not Sure 
 
8. Have you ever had a Pap smear? 
1) Yes – approximate date of last Pap smear (month/year): ____________. At what 
age did you get your first Pap smear? ________ 
2) No 
3) Not Sure 
 
 
The following questions are about YOUR DAUGHTER’S medical history.  Please circle 
your item responses below. 
 
9. In the last year, how often has your daughter seen her primary care 
physician/pediatrician? (Do not include your family’s ACT/survivorship clinic visit 
in this total). 
1) None 
2) 1 to 2 times 
3) 3 to 5 times 
4) 6 to 10 times a year 
5) More than 10 times 
6) Other - Please specify: __________________ 
 
10. Has your daughter received all recommended childhood vaccinations? 
1) Yes 
2) No 
3) Not Sure 
 
11. Has your daughter ever been to a gynecologist (GYN)? 
1) Yes 
2) No 
3) Not Sure 
 
12. Has your daughter ever had a Pap smear? 
1) Yes – approximate date of last Pap smear (month/year): _____________. Age at 
which your daughter received first Pap smear: _______ 
2) No 
3) Not Sure 
 
13. Does your daughter get a Pap test every year? 
1) Yes 
2) No 
3) Not Sure 
 





3) Not Sure 
 
15. Has your daughter ever had a sexually transmitted infection (STI)? 
1) Yes 
2) No 
3) Not Sure 
 




3) Not Sure 
 
17. Has your daughter’s doctor ever recommended that she receive the HPV 
      vaccine? 
1)  Yes 
2)  No 











1. My daughter is allowed to date. 1 2 3 
2. My daughter currently has a boyfriend or is in a 
committed relationship. 
1 2 3 
3. My daughter does not have a current boyfriend and is not 
in a committed relationship, but she has been in the past. 
1 2 3 
4. My daughter is currently sexually active. 1 2 3 
5. My daughter is not currently sexually active, but she has 
been in the past. 
1 2 3 
6. My daughter is not currently sexually active, but I 
anticipate that she will be sexually active before she 
completes high school. 





As girls grow up, mothers may talk with their daughters about ways to keep healthy and 
safe.  Different messages about physical development and sexuality are provided at 
different times in a girl’s life.  Please answer the following questions so that we can learn 













1. I try to see my child’s point of view when we talk 
about sex and sexuality. 
1 2 3 4 5 
2. I talk with my child about HIV. 1 2 3 4 5 
3. I talk with my child about preventing pregnancy. 1 2 3 4 5 
4. I set rules for my child about sex and sexuality. 1 2 3 4 5 
5. I talk with my child about using condoms. 1 2 3 4 5 
6. I talk with my child about body changes that 
happen in adolescence. 
1 2 3 4 5 
7. I talk with my child about sexually transmitted 
illnesses. 
1 2 3 4 5 
8. I encourage my child to ask questions about sex 
and sexuality. 
1 2 3 4 5 
9. I think girls should learn about sex before they 
start their period. 
1 2 3 4 5 
10. I think it’s important to wait until girls are 
emotionally ready to talk about sex. 
1 2 3 4 5 
11. I think it’s important to wait until girls are 
physically mature to talk about sex. 
1 2 3 4 5 
12. I talk with my child about sex and sexuality when I 
think her friends are becoming sexually active. 
1 2 3 4 5 
13. I talk with my child about sex any time my child 
asks me questions. 





14. I talk with my child about sex and sexuality when I 
think she is becoming sexually active. 
1 2 3 4 5 
15. I talk with my child about sex and sexuality before 
she is going out with friends. 
1 2 3 4 5 
16. I use my own experiences when I talk to my child 
about sex and sexuality. 
1 2 3 4 5 
17. I expect my child to follow rules that I set about sex 
and sexuality. 
1 2 3 4 5 
18. I let my child talk as much as I do when we discuss 
sex and sexuality. 






Please answer the following questions. 
  




3) Not Sure 
 




3) Not Sure 
 
3. Information about the HPV vaccine should be made available to adolescent girls. 
1) Yes 
2) No 
3) Not Sure 
 
4. Who should provide information to adolescent girls about HPV vaccination? (choose 




4) School nurse 
5) Health class teachers at school 
6) Friends 
7) Community health center 
8) TV Advertisements 
2. Please rate the following statements about discussing the HPV vaccine with your daughter: 
 











a. Nothing 1 2 3 4 
b. It is a shot to keep girls healthy 1 2 3 4 
c. It is a shot to protect girls from cervical cancer 1 2 3 4 
d. It is a shot to protect girls from HPV 1 2 3 4 
e. Other - Please specify: ___________________ 
_______________________________________ 
1 2 3 4 
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9) Other - Please specify: _______________________ 






Would you be interested in learning about future St. Jude studies which could 











You are finished with this questionnaire.  Thank you for your participation.  Your 
answers to these questions will help us to better understand how parents make decisions 
regarding whether to vaccinate their daughters against cervical and other HPV-related 
cancers.  Please contact Dr. James Klosky at 901-595-4128 if you have any questions 




Information Sheet for 
Human Papillomavirus (HPV) Vaccination among Survivors of Childhood Cancer 
Study 
 You participated in a research study about a family’s decision to have their 
daughters vaccinated against HPV, the virus that causes cervical cancer. A goal of the 
study is to better understand what parents know about cervical cancer risk and what 
factors are important in their vaccination decisions. The research staff is sending you this 
information sheet to provide you with more information regarding HPV vaccination 
among survivors of childhood cancer. 
What is HPV? 
Genital human papillomavirus (HPV) is the most common sexually transmitted 
infection and approximately 50–70% of sexually active women contract HPV at some 
point during their lifetime. Any sexually active person - no matter what race, gender, or 
sexual orientation - can get HPV. HPV infection rates are highest in younger women and 
rise sharply soon after the median age of first sexual activity (which is about 16.9 years 
for females). Specifically, the prevalence of HPV has been estimated to be as high as 
39.6% among 14- to 19-year olds and 49.3% among 20- to 24-year old sexually active 
females. 
What are the symptoms of HPV and health consequences? 
Some HPV infections may be asymptomatic and other HPV infections can cause 
genital warts in men and women. Although most HPV infections are transient (i.e., will 
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resolve on their own within 1 to 2 years), persistent HPV infection is a necessary cause of 
cervical cancer because 100% of cervical cancers are HPV related. Women are screened 
for cervical cancer with Papanicolaou (Pap) testing to identify abnormal cells in the 
cervix that may lead to cancer. 
There are over 100 types of HPV, and approximately 40 strains affect the genital 
tract. Oncogenic HPV strains have been linked to cervical, vaginal, vulvar, penile, and 
anal cancers. Cervical cancer is the second most common cancer among women 
worldwide and is the leading cause of cancer-related deaths among women in developing 
countries. In particular, HPV types 16 and 18 are responsible for 70% of cervical cancers. 
The slow progression of abnormal cell growth due to HPV infection leading to cervical 
cancer is estimated take 10 to 15 years. Therefore, although HPV occurs most often in 
sexually-active adolescents and women between the ages of 15 and 24, cervical cancer 
diagnosis most often occurs in women over the age of 40, with median age at diagnosis 
being 48 years. 
How do people get genital HPV infections? 
HPV is spread through direct skin-to-skin contact during vaginal, anal, or oral sex 
with someone who has been infected with HPV. This can include oral-genital, finger-
genital, and genital-genital contact. A woman is at greater risk for getting HPV-related 
cancers if she smokes cigarettes, began having sex at an early age, has had multiple 
sexual partners, does not use condoms, and/or has given birth to many children. On rare 
occasions, mothers can transmit HPV infections to a newborn during delivery, which can 




Can HPV be treated? 
No. There is no cure for HPV. Most genital HPV infections go away as the body’s 
immune system clears the infection. Ninety percent of HPV infections go away (or are 
cleared from the body) within 2 years. Although the HPV infection itself cannot be 
treated, genital warts can be removed with medications or treatments from a physician. 
Additionally, if a Pap test reveals precancerous cells in the cervix, this can and should be 
addressed immediately. 
Can HPV be prevented? 
Yes! The only sure way to prevent HPV is to abstain from any sexual activity. 
Condoms can provide some, but not total, protection against HPV as condoms do not 
cover the entire genital area. Recently, two vaccines to protect adolescents from HPV 
have been developed: Gardasil (Merck & Co.) and Cervarix (GlaxoSmithKline). They are 
currently available and have been demonstrated to be very safe and clinically effective. 
The Advisory Committee on Immunization Practices (the committee that 
develops written recommendations for the routine administration of vaccines to children 
and adults) recommends routine HPV vaccination for all females aged 11-12 years with 3 
doses of the quadrivalent (Gardasil) or bivalent (Cervarix) HPV vaccine. The vaccine can 
even be started as young as 9 years-of-age (Gardasil) or 10 years-of-age (Cervarix). The 
American Cancer Society guidelines also recommend routine HPV vaccination for all 
girls ages 11 to 12 and as early as 9 at the discretion of doctors. 
Why is HPV vaccination important for childhood cancer survivors? 
Some cancer survivors may have impaired immune systems as a result of their 
cancer treatment. And since we rely on our immune systems to clear HPV once infected, 
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those with depressed immune function are at greatest risk for HPV-related complications. 
As a result, the Children’s Oncology Group has developed Long-Term Follow-Up 
Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancer, which serve 
as the gold standard in the screening for late effects that may arise due to treatment of 
pediatric cancer. These guidelines recommend HPV vaccination for all eligible females 
surviving childhood cancer.  
 
For more information visit these websites: 
American Cancer Society website on HPV vaccination 
http://www.cancer.org/docroot/cri/content/cri_2_6x_acs_recommendations_for_hpv_vac
cine_use_to_prevent_cervical_cancer_and_pre-cancers_8.asp 




Thank you again for participating in our study. If you have further questions 
concerning this project, please call Dr. James Klosky at 901-595-3581. 
 
